Check for updates

OPEN ACCESS

EDITED BY Diana Marisol Abrego-Guandique, Magna Græcia University, Italy

REVIEWED BY Erika Cione, University of Calabria, Italy Je Hyun Seo, VHS Medical Center, Republic of Korea

*CORRESPONDENCE Xiaohua Wang 🖾 wxhua820911@163.com

RECEIVED 27 November 2024 ACCEPTED 10 March 2025 PUBLISHED 26 March 2025

CITATION

Qiu Y, Zhao F, Zheng X and Wang X (2025) The association between dietary vitamins and the risk of sarcopenia in adults aged 20–59: a study based on the NHANES database. *Front. Nutr.* 12:1535190. doi: 10.3389/fnut.2025.1535190

COPYRIGHT

© 2025 Qiu, Zhao, Zheng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The association between dietary vitamins and the risk of sarcopenia in adults aged 20–59: a study based on the NHANES database

Yu Qiu^{1,2,3}, Fengyi Zhao^{1,2,3}, Xiyin Zheng^{1,2,3} and Xiaohua Wang^{4,5,6}*

¹The Department of Clinical Nutrition, Nantong First People's Hospital, Nantong, Jiangsu, China, ²The Department of Clinical Nutrition, Affiliated Hospital 2 of Nantong University, Nantong, Jiangsu, China, ³The Department of Clinical Nutrition, Nantong Hospital of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Nantong, Jiangsu, China, ⁴The Department of Endocrinology and Metabolism, Nantong First People's Hospital 2 of Nantong University, Nantong, Jiangsu, China, ⁶The Department of Endocrinology and Metabolism, Affiliated Hospital 2 of Nantong University, Nantong, Jiangsu, China, ⁶The Department of Endocrinology and Metabolism, Nantong Hospital 2 of Nantong Hospital of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Nantong, Jiangsu, China

Background: Sarcopenia has emerged as a global health concern, but the association between dietary vitamin levels and sarcopenia is not elucidated. This study aims to shed light on the link of 11 dietary vitamins to the risk of sarcopenia in adults at the age of 20–59.

Methods: This cross-sectional study encompassed 2011–2018 data from the National Health and Nutrition Examination Survey (NHANES) for adults aged 20–59. Sarcopenia was defined through the appendicular lean mass to body mass index ratio calculated via Dual-Energy X-ray Absorptiometry (DXA), with sarcopenia determined as a ratio of <0.789 for the male and <0.512 for the female. Multivariate weighted logistic regression assisted in assessing the connection of dietary vitamins with sarcopenia, with results presented as odds ratios (ORs) and 95% confidence intervals (CIs). The dose-response association of various vitamins with sarcopenia was visualized through restricted cubic splines (RCS). Subgroup analyses were carried out to examine the consistency of the aforementioned associations. Sensitivity analysis was performed utilizing propensity score matching (PSM) to adjust for confounding factors and enhance the robustness of the results.

Results: Among the 7,864 participants, 677 (8.6%) had sarcopenia, and 7,187 (91.4%) did not. Multivariate weighted logistic regression and RCS analyses indicated that higher intakes of VA, VB1, VB2, VB3, VB6, VB9, VB12, VC, VE, and VK were notably linked to a lowered risk of sarcopenia (P < 0.05). Among these, VA, VC, and VE exhibited a non-linear negative association with sarcopenia risk (P for non-linear < 0.05), while VB1, VB2, VB3, VB6, VB9, VB12, and VK exhibited a linear negative association (P for non-linear > 0.05). Subgroup analysis yielded largely consistent results. After confounding factors were adjusted through PSM, the results suggest that the intake of VA, VB2, VB6, and VC remains significantly associated with a lowered risk of sarcopenia (P < 0.05).

Conclusion: Higher dietary levels of VA, VB2, VB6, and VC are significantly related to a lower livelihood of sarcopenia. These findings provide new evidence and insights for early dietary interventions aimed at preventing sarcopenia.

KEYWORDS

diet, nutrition, vitamin, skeletal muscle mass, sarcopenia

1 Introduction

Sarcopenia refers to the progressive loss of skeletal muscle mass and physical function (muscle strength or performance) as a person ages and it becomes more prevalent (1). It can lead to plenty of adverse outcomes in the old, such as impaired physical function, diminished quality of life, and elevated risk of mortality, severely impacting their health and life, thereby imposing a substantial strain on families and society. An article from Europe predicts that, over the next 30 years, the number of patients with sarcopenia will increase sharply, with the prevalence of sarcopenia among the old rising from 20.2% in 2016 to 22.3% by 2045 (2). Therefore, sarcopenia poses a major challenge to public health (3-5), with a growing trend of increased healthcare resource utilization and higher medical costs (6). Although sarcopenia has gained considerable attention from most clinicians, a universally accepted and clinically applicable definition remains lacking on an international scale (7). The European Working Group on Sarcopenia in Older People (EWGSOP) defines sarcopenia as a syndrome characterized by the progressive loss of skeletal muscle mass and strength. It is categorized into three stages based on severity: "pre-sarcopenia," "sarcopenia," and "severe sarcopenia." The pre-sarcopenia stage is characterized by low muscle mass but without any impact on muscle strength or physical performance. The sarcopenia stage involves low muscle mass along with either low muscle strength or poor physical performance. Severe sarcopenia is defined as the stage in which all three criteria are met: low muscle mass, low muscle strength, and poor physical performance (8). In addition, the Foundation for the National Institutes of Health (FNIH) defines sarcopenia based on declines in muscle mass, muscle strength, and muscle function, providing corresponding cut-off values based on data from U.S. citizens (9). Its etiology and pathogenesis are multifactorial, including factors such as malnutrition, reduced physical activity, chronic inflammation, and oxidative stress (10). The decline in appetite and digestive function in older adults often leads to insufficient intake or absorption of protein, energy, and trace elements, resulting in malnutrition, which is closely associated with sarcopenia (11). Therefore, nutritional intervention serves as a cornerstone in sarcopenia prevention and treatment. The focus of current research is primarily on the role of macronutrients, such as protein energy metabolism and essential amino acids and their metabolites, in the prevention of sarcopenia. However, large-scale studies exploring the association between vitamins, as micronutrients, and sarcopenia are relatively scarce.

Vitamins are a class of trace organic substances that must be obtained from food and play critical roles in growth, metabolism, and development. They are classified into fat-soluble vitamins, like VA, VD, VE, and VK, and water-soluble vitamins such as VB and VC. It has been demonstrated that multiple vitamins are closely related to sarcopenia (12–14), suggesting that vitamins could serve as potential targets for sarcopenia intervention. Sarcopenia begins to develop gradually in midlife and is accompanied by the deterioration and imbalance of various physiological systems (15). Proper vitamin intake from early stages may lower the risk of muscle loss (16). However, there has yet to be a comprehensive, systematic investigation into the influence of different dietary vitamin intakes on sarcopenia, and existing studies on specific individual vitamins have yielded varying, sometimes contradictory conclusions (17–20).

Therefore, this study delves into the connection of dietary vitamin intake with sarcopenia in Americans between 20 and 59 years old with 2011–2018 data from the National Health and Nutrition Examination Survey (NHANES) and seeks to provide effective nutritional strategies for preventing sarcopenia in adulthood.

2 Methods

2.1 Study population

NHANES is a large-scale cross-sectional survey carried out by the National Center for Health Statistics (NCHS) and the American Centers for Disease Control and Prevention (CDC). It adopts a complicated stratified multistage probability sampling approach to gather health and nutrition information from a nationally representative sample of people who are not institutionalized. It seeks to investigate risk factors for diseases and assess the prevalence of major health conditions. Since 1999, it has been released biennially with continuously collected data. The study protocol was approved by the NCHS Institutional Review Board, and informed consent was gained from the participants. The utilized data were from four cycles of NHANES (2011-2018), comprising 7,864 participants. The dataset is publicly available at https://wwwn.cdc.gov/nchs/nhanes/. This database adheres strictly to ethical standards to safeguard participants' rights and privacy. Additional ethical information is detailed at https://www.cdc.gov/ nchs/nhanes/irba98.htm.

The inclusion criteria for this study were: participants with recorded Dual-energy X-ray Absorptiometry (DXA) scan results, key outcome variables for the diagnosis of sarcopenia, and complete dietary data, including vitamin intake, as well as complete covariate data. The exclusion criteria were: participants who did not undergo a DXA scan and did not have key outcome variables for the diagnosis of sarcopenia, and had incomplete or no dietary data (including vitamins), and incomplete covariate data (Figure 1).

2.2 Dietary vitamins

Nutritional data were gathered after two 24-h dietary recall interviews. Participants were asked about the type and amount of foods, beverages, and dietary supplements had in the past 24 h. The first dietary recall was performed in person at the Mobile Examination Center (MEC), and the second was carried out by phone 3 to 10 days later. To obtain more accurate estimates of the nutrients in the foods, beverages, and supplements consumed, trained interviewers used the Automated Multiple-Pass Method (AMPM) system (http://www.ars.usda.gov/nea/bhnrc/fsrg) for diet data collection. This interview system assisted by computer employs a standardized five-step method to assess current dietary intake and minimize underreporting. The dietary vitamins



extracted for this study encompass VA, VB1, VB2, VB3, VB6, VB9, VB12, VC, VD, VE, and VK.

2.3 Definition of sarcopenia

In adherence to the recommended sarcopenia diagnosis criteria of the Foundation for the National Institutes of Health (FNIH) (9), as well as previous studies (21, 22), sarcopenia is defined by the ratio of appendicular lean mass (ALM) to body mass index (BMI). The thresholds for sarcopenia are set at ALM/BMI values of <0.789 for males and <0.512 for females. ALM measurements are performed via Dual-Energy X-ray Absorptiometry (DXA) by trained and certified radiologic technicians. These measurements are obtained through a Hologic Discovery Model A densitometer (Hologic, Inc., Bedford, Massachusetts) with Apex 3.2. The DXA protocol is in the Body Composition Procedures Manual and available at https:// www.cdc.gov/nchs/nhanes/index.htm.

2.4 Covariates

In our study, a standard interview questionnaire was utilized for gathering information on gender, age, ethnicity, education, marital status, poverty-to-income ratio (PIR), hypertension and malignancy history, alcohol consumption, smoking, and physical activity. BMI (kg/m²) was obtained through anthropometric measurements, while diabetes-related information was gathered through questionnaires and laboratory tests. Ethnicity was classified as Mexican American, non-Hispanic White, non-Hispanic Black, or Other. Education was divided into less than high school, high school or equivalent, and college or higher. Marital status was grouped as married or cohabitating, widowed, divorced or separated, and never married. Smoking involved non-smokers, former smokers (individuals who had smoked 100 or more cigarettes and quit), and current smokers (those who had smoked over 100 cigarettes and are smoking). Alcohol consumption was divided into drinkers and non-drinkers based on whether the individual consumed 12 or more alcoholic beverages in the past year. Physical activity was measured in metabolic equivalent (MET)-minutes every week. The diabetes diagnosis standards include: (1) being informed by a doctor or healthcare professional of having diabetes, (2) a hemoglobin A1c (HbA1c) level \geq 6.5 mmol/L, (3) a fasting blood glucose level (FGLU) \geq 7.0 mmol/L, (4) current use of anti-diabetic medication, or (5) current use of insulin.

2.5 Statistical analysis

Our statistical analyses accounted for the intricate, multistage, tiered, and clustered sampling of NHANES. Sample weights were appropriately allocated based on NHANES guidelines, with the WTDR2D weighting applied to combine samples from four distinct survey cycles. Participants were categorized into the sarcopenia group and the non-sarcopenia group. Categorical variables are presented as unweighted n (weighted %), and statistical comparisons were performed using the Rao-Scott chisquare test. Continuous variables, after the Anderson-Darling test, were found to follow non-normal distributions and are presented as medians (interquartile range), with comparisons made via the Mann-Whitney U test. Weighted logistic regression helped us examine the link of dietary vitamin intake to sarcopenia risk, with results displayed as ORs and 95% CIs. Three logistic regression models were constructed: Model 1 (unadjusted), Model 2 (adjusted for gender, age, ethnicity, education, marital status, PIR, and BMI), and Model 3 (adjusted for the variables in Model 2, history of diabetes, hypertension and malignancy, smoking, alcohol

10.3389/fnut.2025.1535190

consumption, as well as physical activity. An RCS model assisted in visualizing the dose-response association between vitamin levels and sarcopenia. Subgroup analyses were conducted in terms of gender, age, ethnicity, educational level, marital status, diabetes, hypertension, malignancy, drinking, and smoking to assess the stability of the relationship between vitamins and sarcopenia. PSM was employed in the sensitivity analysis to assess the robustness of the outcomes. All analyses were conducted with the help of R. A two-tailed *p*-value < 0.05 signified statistical significance.

3 Results

3.1 Baseline characteristics of the study population

Seven thousand eight hundred and sixty four participants aged 20–59 were encompassed, with the majority being non-Hispanic white. The male-to-female ratio was approximately equal. They were classified as the sarcopenia group (n = 677) and the non-sarcopenia group (n = 7,187). The former group was older and had lower household income, higher BMI, and prevalence of diabetes and hypertension, as well as less alcohol consumption and physical activity (P < 0.05). Statistically significant differences also existed between them in ethnicity and educational level distribution (P < 0.05). Other baseline characteristics are presented in Table 1. The vitamin intake levels between the two groups showed statistically significant differences (P < 0.05), except for VD (P = 0.08).

3.2 Association between vitamin intake and sarcopenia risk

The association between vitamin intake levels and sarcopenia risk is shown in Table 2. Each vitamin was treated as a categorical variable, and the associations between 11 vitamins and the risk of sarcopenia were examined through three weighted logistic regression models. After adjusting for covariates, vitamins A, B1, B2, B3, B6, B9, B12, C, E, and K showed negative associations with sarcopenia (OR < 1, P < 0.05), while VD did not show a significant relation to sarcopenia risk (P > 0.05). Specifically, in contrast to the lowest quartile (Q1), the third quartile (Q3) levels of vitamins A, B1, B2, B3, B6, B9, B12, C, E, and K were all negatively correlated with the risk of sarcopenia [(VA, OR = 0.486, 95%CI:0.334-0.708, P < 0.001), (VB1, OR = 0.582, 95%CI:0.372-0.911, P = 0.019), (VB2, OR = 0.442, 95%CI:0.294-0.663, P < 0.9110.001), (VB3, OR = 0.569, 95%CI:0.377–0.858, P = 0.008), (VB6, OR = 0.529, 95%CI:0.339–0.824, P = 0.006), (VB9, OR = 0.620, 95%CI:0.407-0.942, P = 0.026), (VB12, OR = 0.635, 95%CI:0.449-0.898, P = 0.011), (VC, OR = 0.664, 95%CI:0.450-0.980, P = 0.04), (VE, OR = 0.519, 95%CI:0.345-0.780, P = 0.002), and (VK, OR = 0.564, 95%CI:0.359-0.887, P = 0.014)].

The dose-response association of vitamin levels with the risk of sarcopenia in the study population was probed (Figure 2) in the RCS analysis. After multivariable adjustment, no notable relationship was found between VD levels and the incidence of sarcopenia (P for overall > 0.05), which is consistent with the

results of logistic regression. Intake levels of vitamins A, C, and E exhibited a non-linear negative link to sarcopenia (*P* for overall < 0.001, P for non-linear < 0.05), while intake levels of vitamins B1, B2, B3, B6, B9, B12, and K showed a linear inverse relationship with sarcopenia (*P* for overall < 0.05, P for non-linear > 0.05).

3.3 Subgroup analysis and interaction

Subgroup analysis was performed after adjustment for gender, age, ethnicity, education, marital status, PIR, BMI, medical history (hypertension, diabetes, and malignancy), smoking, drinking, as well as physical activity, for the evaluation of the link of vitamin intake to sarcopenia in different subgroups, and to explore potential interactions between vitamins and other variables (Figure 3). In the subgroup analysis by age, the intake of VA, VB3, VB9, VB12, VE, and VK in individuals aged 50 and older was negatively associated with the risk of sarcopenia (P < 0.05). In the subgroup analysis by gender, VA, VB3, VC, VE, and VK intake in females was negatively related to sarcopenia risk (P < 0.05), while in males, the intake of vitamins A, B3, B6, B9, B12, and E was negatively correlated with sarcopenia risk (P < 0.05). An interaction was observed between education and VA on the risk of sarcopenia (P for interaction = 0.048). In individuals with at least a high school education, a higher intake of VA was inversely correlated with the risk of sarcopenia (P < 0.05). In the diabetes subgroup analysis, higher intake of vitamins A, B3, and E was correlated with a significant sarcopenia risk reduction (P < 0.05). In the hypertension subgroup, increased intake of vitamins A, B3, B12, E, and K was notably related to a lower sarcopenia risk (P < 0.05). In the malignancy subgroup, VA and VK intake had a negative link to sarcopenia risk (P < 0.05). In the alcohol consumption subgroup, the relationship between higher vitamins A, B2, B3, B9, B12, C, E, and K intake and reduced sarcopenia risk was more pronounced (P < 0.05). For smokers, higher intake of vitamins A, B1, and B3 was notably linked to a lower risk of sarcopenia (P < 0.05).

3.4 Sensitivity analysis

A sensitivity analysis was carried out utilizing PSM, which led to the inclusion of 1,354 participants, with 677 in the sarcopenia group and 677 in the non-sarcopenia group. PSM adjusted for variables including gender, age, race, education, marital status, PIR, BMI, medical history, total caloric intake, smoking status, alcohol consumption, and physical activity, thereby minimizing the confounding differences between the sarcopenia and nonsarcopenia groups. Subsequently, three weighted logistic regression models were employed to investigate the potential associations between 11 vitamins and the risk of sarcopenia, as presented in Table 3. In Model 3, higher intakes of VA, VB2, VB6, and VC were significantly negatively associated with the risk of sarcopenia (OR < 1, P < 0.05). Specifically, in comparison to Q1, the Q3 levels of VA, VB2, VB6, and VC showed a negative correlation with the risk of sarcopenia [(VA, OR = 0.551, 95%)

TABLE 1 Basic characteristics of participants by sarcopenia in NHANES 2011–2018.

Variables	Overall <i>N</i> = 7,864	Non-sarcopenia participants $N = 7,187$	Sarcopenia participants $N = 677$	<i>P</i> -value
Gender				0.2
Male	3,822 (50%)	3,489 (50%)	333 (54%)	
Female	4,042 (50%)	3,698 (50%)	344 (46%)	
Age	39 (29,50)	39 (29,50)	46 (34,55)	<0.001
Ethnicity				< 0.001
Mexican American	1,083 (10%)	861 (9.1%)	222 (25%)	
Non-Hispanic White	2,947 (62%)	2,744 (63%)	203 (51%)	
Non-Hispanic Black	1,680 (11%)	1,632 (12%)	48 (3.4%)	
Other Ethnicity	2,154 (17%)	1,950 (16%)	204 (21%)	
Education				< 0.001
Less than high school diploma	1,218 (11%)	1,038 (10%)	180 (20%)	
High school diploma/equivalent	1,701 (22%)	1,516 (21%)	185 (29%)	
College or above	4,945 (67%)	4,633 (69%)	312 (51%)	
Marriage				0.072
Married/cohabitation	4,717 (61%)	4,291 (61%)	426 (63%)	
Widow/divorce/separation	1,090 (13%)	975 (13%)	115 (17%)	
Unmarried	2,057 (25%)	1,921 (26%)	136 (21%)	
PIR	2.97 (1.40,5.00)	3.05 (1.45,5.00)	1.97 (1.06,3.75)	< 0.001
BMI (kg/m ²)	28 (24,32)	27 (24,32)	34 (30,40)	< 0.001
Log (VA) (mcg)	6.27 (5.81,6.70)	6.29 (5.83,6.72)	6.03 (5.52,6.50)	< 0.001
Log (VB1) (mg)	0.54 (0.19,0.93)	0.55 (0.20,0.94)	0.43 (0.12,0.77)	0.005
Log (VB2) (mg)	0.79 (0.44,1.20)	0.79 (0.45,1.22)	0.63 (0.26,1.01)	< 0.001
Log (VB3) (mg)	3.34 (3.00,3.67)	3.34 (3.00,3.69)	3.21 (2.86,3.54)	< 0.001
Log (VB6) (mg)	0.83 (0.44,1.34)	0.85 (0.45,1.36)	0.67 (0.30,1.02)	< 0.001
Log (VB9) (mcg)	6.34 (5.92,6.82)	6.36 (5.93,6.84)	6.25 (5.80,6.65)	< 0.001
Log (VB12) (mcg)	1.80 (1.17,2.53)	1.81 (1.18,2.55)	1.61 (1.06,2.22)	0.002
Log (VC) (mg)	4.38 (3.56,5.02)	4.40 (3.57,5.03)	4.12 (3.42,4.81)	< 0.001
Log (VD) (mcg)	1.65 (0.81,2.65)	1.66 (0.83,2.66)	1.49 (0.62,2.48)	0.080
Log (VE) (mg)	2.09 (1.72,2.47)	2.11 (1.73,2.48)	1.93 (1.56,2.25)	< 0.001
Log (VK) (mcg)	4.49 (3.97,5.03)	4.52 (3.99,5.05)	4.25 (3.74,4.76)	< 0.001
Ratio of Diabetes	847 (8.1%)	693 (7.0%)	154 (22%)	< 0.001
Ratio of Hypertension	1,860 (22%)	1,636 (21%)	224 (38%)	< 0.001
Ratio of Malignancy	333 (5.3%)	289 (5.1%)	44 (8.1%)	0.088
Ratio of Alcohol drinking	6,193 (83%)	5,720 (84%)	473 (75%)	< 0.001
Smoking status				0.6
Never	4,799 (60%)	4,373 (60%)	426 (61%)	
Former	1,344 (19%)	1,214 (19%)	130 (20%)	
Current	1,721 (21%)	1,600 (21%)	121 (19%)	
PAM (MET-min/week)	1,920 (480,5,720)	1,920 (480,5,760)	1,200 (0,3,960)	<0.001

PIR, poverty income ratio; BMI, body mass index; VA, vitamin A; VB1, vitamin B1;VB2, vitamin B2;VB3, vitamin B3;VB6, vitamin B6; VB9, vitamin B9; VB12, vitamin B12; VC, vitamin C; VD, vitamin D; VE, vitamin E; VK, vitamin K; MET, metabolic equivalent of task; PAM, physical activity MET. All continuous variables deviated [IQR: P50 (P25, P75)]; categorical variables were denoted as unweighted n (weighted%). Categorical and continuous variables were compared via chi-squared and Wilcoxon rank-sum tests with Rao & Scott's correction for complex surveys.

Variables	The range of dietary vitamin levels	Model 1	<i>P</i> -value	Model 2	<i>P</i> -value	Model 3	P-value	
Log (VA) (mcg)								
Q1	-0.69-5.72	1		1		1		
Q2	5.72-6.64	0.541 (0.416,0.702)	< 0.001	0.505 (0.375,0.680)	< 0.001	0.501 (0.375,0.671)	< 0.001	
Q3	6.64-8.90	0.454 (0.317,0.652)	< 0.001	0.489 (0.336,0.712)	< 0.001	0.486 (0.334,0.708)	< 0.001	
p for trend			< 0.001		< 0.001		< 0.001	
Log (VB1) (mg)								
Q1	-3.05-0.16	1		1		1		
Q2	0.16-0.90	0.913 (0.689,1.209)	0.519	0.858 (0.629,1.171)	0.328	0.848 (0.616,1.169)	0.306	
Q3	0.90-6.46	0.592 (0.406,0.861)	0.007	0.590 (0.378,0.919)	0.021	0.582 (0.372,0.911)	0.019	
p for trend			0.006		0.019		0.017	
Log (VB2) (mg)								
Q1	-2.78-0.36	1		1		1		
Q2	0.36-1.12	0.636 (0.477,0.848)	0.003	0.607 (0.428,0.860)	0.006	0.624 (0.441,0.884)	0.009	
Q3	1.12-5.36	0.459 (0.315,0.670)	< 0.001	0.425 (0.284,0.637)	< 0.001	0.442 (0.294,0.663)	< 0.001	
p for trend			< 0.001		< 0.001		< 0.001	
Log (VB3) (mg)								
Q1	0.32-2.96	1		1		1		
Q2	2.96-3.64	0.826 (0.622,1.097)	0.183	0.737 (0.536,1.012)	0.059	0.736 (0.533,1.017)	0.063	
Q3	3.64-7.83	0.561 (0.386,0.817)	0.003 0.547 (0.363,0.82		0.005 0.569 (0.377,0.858)		0.008	
p for trend			0.002		0.004		0.007	
Log (VB6) (mg)								
Q1	-2.59-0.39	1		1		1		
Q2	0.39-1.26	0.788 (0.590,1.052)	0.105	0.807 (0.567,1.149)	0.228	0.812 (0.568,1.160)	0.245	
Q3	1.26-9.21	0.469 (0.322,0.683)	< 0.001	0.527 (0.339,0.820)	0.005	0.529 (0.339,0.824)	0.006	
p for trend			< 0.001		0.005		0.005	
Log (VB9) (mcg)								
Q1	2.60-5.89	1		1		1		
Q2	5.89-6.78	0.799 (0.592,1.080)	0.142	0.749 (0.536,1.048)	0.09	0.738 (0.526,1.036)	0.077	
Q3	6.78-9.76	0.603 (0.420,0.865)	0.007	0.627 (0.414,0.952)	0.029	0.620 (0.407,0.942)	0.026	
p for trend			0.006		0.026		0.024	
Log (VB12) (mcg)								
Q1	-5.30-1.11	1		1		1		
Q2	1.11-2.42	0.897 (0.683,1.179)	0.43	0.815 (0.582,1.141)	0.228	0.819 (0.581,1.155)	0.248	
Q3	2.42-11.00	0.586 (0.419,0.820)	0.002	0.633 (0.452,0.887)	0.009	0.635 (0.449,0.898)	0.011	
p for trend			0.002		0.008		0.011	
Log (VC) (mg)								
Q1	-2.30-3.55	1		1		1		
Q2	3.55-5.00	0.831 (0.624,1.108)	0.204	0.952 (0.682,1.329)	0.77	0.916 (0.653,1.285)	0.604	

TABLE 2 Multi-variate adjusted odds ratios (95% CIs) of risks of Sarcopenia in relation to different dietary vitamins levels among participants in NHANES 2011–2018.

(Continued)

Variables	The range of dietary vitamin levels	Model 1	<i>P</i> -value	Model 2	<i>P</i> -value	Model 3	<i>P</i> -value				
Q3	5.00-9.64	0.589 (0.422,0.823)	0.002	0.697 (0.471,1.033)	0.071	0.664 (0.450,0.980)	0.04				
p for trend			0.002		0.076		0.042				
Log (VD) (mcg)											
Q1	-3.00-0.77	1		1		1					
Q2	0.77-2.56	0.847 (0.649,1.105)	0.217	0.769 (0.555,1.064)	0.111	0.760 (0.545,1.059)	0.103				
Q3	2.56-7.19	0.707 (0.505,0.990)	0.044	0.782 (0.544,1.124)	0.179	0.739 (0.517,1.059)	0.097				
p for trend			0.041		0.161		0.087				
Log (VE) (mg)											
Q1	-2.81-1.67	1		1		1					
Q2	1.67-2.42	0.749 (0.553,1.014)	0.061	0.839 (0.598,1.178)	0.305	0.854 (0.606,1.204)	0.359				
Q3	2.42-5.04	0.472 (0.318,0.699)	< 0.001	0.506 (0.333,0.768)	0.002	0.519 (0.345,0.780)	0.002				
p for trend			< 0.001		0.002		0.002				
Log (VK) (mcg)											
Q1	-0.36-3.93	1		1		1					
Q2	3.93-4.99	0.750 (0.556,1.013)	0.06	0.700 (0.496,0.989)	0.043	0.703 (0.495,0.999)	0.049				
Q3	4.99-10.72	0.486 (0.330,0.715)	< 0.001	0.560 (0.355,0.885)	0.014	0.564 (0.359,0.887)	0.014				
p for trend			< 0.001		0.013		0.014				

TABLE 2 (Continued)

Data are presented as OR (95% CI) unless otherwise indicated. Model 1, without adjustment. Model 2, adjusted for gender, age, ethnicity, educational level, marriage, PIR and BMI. Model 3, adjusted for model 2 variables as well as the disease history (diabetes, hypertension, and malignancy), smoking status, alcohol drinking status, and physical activity.

CI: 0.368–0.824, P = 0.005), (VB2, OR = 0.612, 95% CI: 0.401– 0.932, P = 0.023), (VB6, OR = 0.570, 95% CI: 0.369–0.880, P = 0.013), and (VC, OR = 0.639, 95% CI: 0.431–0.947, P = 0.027), respectively]. Other vitamins, including VB1, VB3, VB9, VB12, VD, VE, and VK, did not exhibit significant associations (P > 0.05).

4 Discussion

In our study, the association between 11 vitamins and the incidence of sarcopenia was explored. Both non-linear and linear associations were identified between various vitamins and the occurrence of sarcopenia. Our findings suggest that higher intakes of VA(OR = 0.486), VB1 (OR = 0.582), VB2 (OR = 0.442), VB3 (OR = 0.569), VB6 (OR = 0.529), VB9 (OR = 0.620), VB12 (OR = 0.635), VC (OR = 0.664), VE (OR = 0.519), and VK (OR = 0.564) are notably related to a lowered incidence of sarcopenia. Specifically, VA, VC, and VE demonstrated a nonlinear negative association with sarcopenia, whereas vitamins B1, B2, B3, B6, B9, B12, and K exhibited a linear negative association. A notable association was not found between VD intake and the occurrence of sarcopenia. Our sensitivity analysis suggests that the results of negative correlations between VA, VB2, VB6, VC, and sarcopenia were more robust. This is the first large-scale study that comprehensively investigates the association of the intake of different vitamins with sarcopenia.

The association between VD and sarcopenia is a particularly intriguing topic. Several in vitro and animal studies have suggested that VD influences muscle cell proliferation, differentiation, and calcium homeostasis, playing a pivotal role in muscle physiology (23, 24). However, these findings are not always reflected in population-based studies. A Brazilian study involving 159 individuals aged 80 and above, which assessed VD intake through a 1-day dietary record (including supplements), showed no statistically significant association of VD intake with muscle mass, as measured by DXA (25), which aligns with our findings. Nevertheless, Swedish research of 719 individuals aged 70 found that VD intake, assessed via the diet history method, had a significantly positive association with the limb skeletal muscle mass index calculated via DXA (r = 0.219, P = 0.004), but no association was observed with walking speed or grip strength (26). A recent meta-analysis involving 15 studies and 2,866 participants aged 65 and above, examined the influence of VD on muscle strength and physical performance of the old in the community. The metaanalysis indicated that most studies reported no amelioration in muscle strength or physical performance after VD was supplemented either with or without calcium supplementation (27). The inconsistent conclusions across different population studies may arise from variations in study design, dosage, and baseline 25(OH)D levels in participants. Therefore, the relationship between VD and muscle health in the middle-aged and the old remains complex and is not fully defined, warranting further largescale, rigorously designed studies.



FIGURE 2

RCS analysis of the vitamin intake and sarcopenia risk with a 3-knot restricted cubic spline model based on Model 3. (A–K) Represented the association of vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, and sarcopenia, respectively. Odds ratios were standardized to 1.00 for median vitamin intake. The red line represented the trend, and the red area was the 95% confidence interval. P for overall assessed the model's explanatory power, and P for non-linear signified the significance of the non-linear association.

27 C				0.637	Ve	usades P	v	Warele 81	CREATING Province	P for interaction	Variables	N Viter	in 82 09(89501) Pr	alue P for interaction .	Yatisties	N Visenia	183 CREMINCE Picada	P for Interaction	VENDORS		vvismin B	to uniteraciji Pre	.000
Male	3.822	-	0.200.00.0.000.0.007	0.000	3 Sec	a		1.1		0.301	Gee			0.661	500	1.1		0.200	8 Sex				
Female	4.042		0.6493.51.0.800 +3.001		D -	799 5	1,822		0.35(0.52,1.08) 0.12		1 Main	5,822	0.67(0.44,1.02) 0.0	10	Mate	1,822	0.51(0.37,0.71) +0.001		A Country	1.8.22		0.700.501.900 0.05	2
				0.315		restate #	1,042		0.89(0.64,1.26) 0.5		Fexale	4,042	0.71(0.47,1.10) 0.1	r	Female	1,012	0.66(0.40,1.00) 0.047		Foras	4,040		0.30(0.03,125) 0.0	÷
10	1 995	-	0.630.301.013 0.055		14	<i>p</i>				0.498	Apr			0.863	Apr			0.195	147				
10-40	1.828		0.9(0.60,1.28) 0.6			+30 5	.995	_	0.99(0.99,109) 0.8		+30	1,005	0.02(0.41,1.05) 0.0		*50	(995	0.78(0.49,1.23) 0.3		100	1.000	G 1	4.90(0.06.16) 1.8	in.
12.50	1.884	-	0.71/2.53.0 80. 0.029			10-40 5	.908		0.66(0.44,1.01) 0.054		30-48	1,920	0.54(0.36,0.01) 0.0	10	30-40	(908	0.56(0.35,0.89) 0.016		20-0	1.000	-	4.370/42.4117 40.0	
	1,956	-	0.530.44.0.800 0.011			43-50 5	584		0.8(0.51,1.95) 0.5		40-04	1,884	0.00(0.43,0.98) 0.0	11	43-56	1,964	0.54(0.34),0.88) 0.014		6530	1.000		4000411177 43	2
101				0.677		×90 5	1,900		0.98(3.68,12)) 0.5		×+50	1,555	- 0.69(0.38,1.26) 0.3		>100	1,000	0.45(0.31,0.85) 0.016		for a second sec		-	another cent av	-
Anican American	1.013		0.85/2 (0.0.85) 0.003		PGe	co		-		0.124	Race			0.163	Rate			0,454	Marine American	4 8 6 8	1		
dan Misponio White	2,947	-	0.88(2.54.0.8) 0.007			Jeccan American 1	1,083 -	-	0.56(3.58,0.81) 0.001		Intoican American	1,083 >	0.44(0.37,0.76) 0.0	16	Motioan American	1.083	0.17(0.47,1.29) 0.3		New Internet White	1841	1.00	4 100 10 1 200 4 4	
lan Hisponis Disek	1,680	-	0.00(3.68,1.40) =3.0			Jarobispanis White 2	2,047	_	0.8993.66,1.301 0.5		Non-Hispanis White	2,607	 0.78(0.48,1.26) 0.3 		Non-Hispanic White	2.947	0.47(0.30.0.75) 0.902		Narchiganic Villa	1.000		4.4000.00.000 4.4	
Wher Rapp	2.954	-	0720356.0.500 0.041			Antresponse posses		- · ·	Contraction of the second		Hon-Hapards Black	1,680	0.00(0.43,1.02) 0.0	13	Nor-respond poor	(080	0.6608.42,1.905 8.91		Class Base	3.004	the second second	4.000 55.540 4.01	
ucition				0.540		And Palace 2	C. 184		producer red ore	6.178	Other Nace	2,154	0.72(0.82,1.01) 0.0	18	One Hade	2104	0.13(0.40(1.00) 0.12	0.000	Education			a support a set	-
ess that high school diploma	a 1,218 -	-	1.01(3.74,1.38) >3.9			I see they high asheed distance	1040	-	0.730.01.010.010	6.429	Education			0.297	Long Barry black and sind and		0.0300.0310.000	0.000	Less that high school distorts	1 1 1 1	-	4400433403 440	-
ligh school diplemaleosivalen	ent 1.701	-	0.73(0.54.0.55) 0.039			Link open of the second open a	1754	-	0.600.00.000		Less than high action diplana	1,210	0.55(0.34(0.06) 0.0	н	Citis Carriege active Optical		0.0000000000000000000000000000000000000		Nish salari daharahar balari	1 1 201		4.5300 37.6 201 -0.0	004
cellege er above	4.945		0.59(2.46.0.70) +3.001			College or shope	1045	-	0.0000.001000.07		High school diplomatequivates	1,201	0.49(0.33,0.71) <0	001	Colore of March	1945	0.535.340.875 5.505		College or show	4.945		4 930 68 1 252 4 4	4
ariaga				0.545	Ma	aniana .		_		6.347	College or abeve	4,945	- 0.8290.83.1.281 0.3		Manipus			0.774	Maniaca				
Mariedhobabilation	4/17		0.81(3.50,0.75) +3.001			Maria di schabaltationo	1717	-	030054300 0000		Interniogo			0.467	Maning	1717	0.000 41.0000 0.000	0.204	Maximilaritation	4 ***	the second second	4 800 54 3 125 4 3	
Videwideoroelseparation	1,000	-	0.89(3.60.1.31) 0.5			The second secon	000	- I	1333 78 1 801 04		Interledicababilition	4,757	0.62(0.43,0.06) 0.0	39	Mildred Control and American		0.000 41157 5.5		Milder Managements	1.000		A 8700 48 4 680 A 7	÷
amaried .	2.057		02003561.920 0.2			Descaled	1087	-	0100301010103		Widow/dvorse/separation	1,090	+ 1.00(0.51,1.96) >0	P	internal of	000	0.0000000000000000000000000000000000000		1 month and the second parameters	2.007	the state of the s		
tia of Diabeles				0.805		dia of Distories				0.617	Unmarted	2,067	0.07(0.541.31) 0.3		Potio of Cabular			0.96	Rote of Contestion				-
100	847	-	853.0 08.0.84.0.85.0			5m (WZ -		0200431540.015		Ratio of Diabetas			0.287	You and a second s		0.550 TO 0.00 0.005		Yes	117	the second second		
	7.017 -	-	0.7293.62.0.830 +3.001			AM	2017		0.000.021.531.02		Yes	647	0.70(0.41,1.22) 0.3		100 C	1011	0.000 0.000 0.000			1447		A TTO (8 4 81) 87	
tig of Hypetensian				0.894	De	tio of Menertension				0.105	190	7,017	0.6890.47,0.97) 0.0	12	Pinto of Manufacture		0.000-4000.800 90.001	0.000	frain state and state	1,017	- T	4.17(0.08,101) 0.00	
14	1.810	_	0.200.04.0.820 0.011			The second se	1000	_	0.000.000.000		Plato of Hypertension			0.183	View		0.000.0000.000		And a repeated and				_
	6.004	-	0.23(0.61.0.80) +0.001				1000	-	070051100 0002		Yes	1,850	0.02(0.49,1.09) 0.5		100	004	0.0000.00000 0000		res .	1.600	1.1	- x30p.01(147) 4.8	
in of biologenese				0.234		and the second		-	enderstradi ottas	6.343	No	6,004	0.65(0.44(0.05) 0.0	и	for all the second		0.0000-44(0.00) 10.004		64	0.004		4.010.08.2.90) 0.00	10
N	232		049325.070 0.4%			Sin .	- 10	-	0.789.76.1421.0.4		Ratio of Malignancy			0.489	You You		0.448 35 1 300 C	0.000	Home of Homenancy	-	5 m		
	7.633	- 1	0.7202.62.0.830 52.000			All Control of Control	101		050061110 02		Yes	333	0.30(0.13.1.21) 0.1		100		0.000 40(1.00) 0.13		Tes	202		0.9600.27.1.160 0.11	4
in al Manhal distance	1,000			6.744		and the bar stations		-	vagoor.crij va	6.308	No	7,501	0.7(0.51,0.50) 0.0	17 C		(361	0.860-800773 00.001		Na	7,551		0.80(0.62,1.05) 0.11	м
a criectica criming				6240	100	So of Hoolo Datesty				67.00	Ratio at Abshol drinking			0.669	Natio of Allooko, Braking			0.01	Ratio of Alcohol dtinking				
	1,000		Call(2.07,0.82) 42,001						offer and the offer		Yes	6,193	0.6590.50.0.07) 0.0	13	rea	5,193	0.5/(0.41)0.745 40.004		Tes	4,193		0.70(0.68,1.08) 0.14	36
	(arr		erapise, rasp. e.r.					-	orderer tog op	6.346	Pho	1,071	0.07(0.32, 1.37) 0.3		NO	1,011	0.03(0.30,1.05) 0.073		Na	1.871		- 0.78(0.48,1.36) 0.4	4
using scales				6.111		Contra and and and and and and and and and an	100	-	0.000 FE 4.001 0.0	67.00	Smoking status			0.624	swoung stress			0.063	Smoking status		1		
RALL.	4,799		0.0002.46.0740 42.001						onigrou, racy our		Herer	4.799	0.6200.30.1.00 0.0	14	Nendr	(AB	0.5/(6.39(0.82) 6.004		blevor	4,799		4.83(0.66,1.15) 4.3	4
oeneer	1,314		0.00(0.04,1.17) 0.3			Cardo -			Contraction and		Famer	1344	0.000515.071 0.5		Pomer	0344	0.19(0.40,1.41) 0.4		Former	1,344		- 0.87(0.64,1.35) 0.5	s
and the second s	Un -	-	D.86(3/D,1.33) D.8		`	Janen. 1	Con La	_	ordered and ones		Owned	1.721	0 700 48 1 171 03		Centent	(721 m-	0.59(0.25,0.82) =0.001		Current	1.721	5e 1	0.53(0.37.0.76) +0.0	1004
	0.4	1 1					0.3	1 12	,							0.3 1	6.7				4 1	16	
dables	N 154	lamin 83	OR(85%CI) P value	P for interaction		variables *	N	Vitamin 812	CR(191.CI) Pvala	P for interaction	Verlables	N Viter	AND OREMINED PY	ine Pferintessettes	Water And	Mittania	E DESERT	R for interaction	Variables	N	Wamin F	K ORREVCE PVF	raise
x				0.00	$\mathbf{\Lambda}$	den .		- 1 - C		0.438	TT ix	1 1		0.590	T				540		1.1.1		
foke	3,822		0.65(0.47,0.04) 0.002			Mele	3,822		3.85(3.73,0.09) 0.038		Male	3,822	0.91078.1.00 0.2		Mah	677	0.7303.67.0.070 0.0073		Male	3,822		0.00(0.57,1.12) 0.2	1
erale	4,942		0.86(0.63,1.19) 0.4		U.	Fexale	4,642		0.00(0.18,1.04) 0.14		Fensie	4,042	0.84(0.72,1.00) 0.0	4	Forste	.012 .	0.5592.42.0.711 +0.001	J	Female	4,942		0.61(0.46,0.75) +0.0	.001
		_		0.268	- /	249		_		0.75	Apr			0.815	A90			0.165	Age				
-30	(996 -	-	0.83(0.83, 1.3) 0.4			<30	1,996		0.96(0.741.25) 0.8		+30	1,995	0.03(0.75,1.16) 0.8		-30	.995	0.63(3.41.0.56) 0.042		<30	1,996		0.61(0.64,0.86) 0.00	/05
0.40	1,028 -+	-	s-solored orest oress			20-18	1,928		0.71(0.56,0.89) 0.004		30-03	1,928	0.83(07,5.09) 0.2		33-40	505	1 003 79,1433 0.7		30.40	1,828			7
13.10	1,894	-	0.8(0.42,1.91) 0.8			43-58	1,994		0.95(0.78,1.17) 0.0		40-00	5,994	0.89(0.75,1.09) 0.3		43.50		0.47(3.29,0.78) 0.005		43-50	1,884 2		0.59(3.38,0.83) 0.02	.23
n a second	0.00		andreatment orga			>+50	1,556	-	315(314(356) 3.054		>=50	1,950	0.06(0.74(1) 0.0		>+60 1	,196	0.58(3.39,0.88) 0.008		>100	1,856 ;	-	041(241(032) 0.01	09
an a				6776	12	eace				0.734	Place			0.5%	Race			0.434	Mace		1		
the second second second	1,013		- 200 (3 + 00) 0 4 4			Mexcan Albertan	1,005	_	0.940.78,1.329 0.7		Mettican American	5,063	0.66(0.72,1.01) 0.0	6	Moxican American 1	- CB3,	0.50(3.41,0.80) 0.082		Mobion American	1,005	1	0.07(1.55,0.86) 0.00	-30
arrespent, renav	1.000		6 200 (8 5 15) 0.04			Non-Propose Wents	2,947	-	3.649.71.0.09 3.0%		Hos-Hispanic White	2,947	0.90(0.80,1.08) 0.2		Non-Hispania White 3	.047	0.63(3.46,0.86) 0.004		Non-mopanie white	2.947		1720.001.000 0.00	<u></u>
	1.000		5 700 FE 1 17 02			Kar. Popula Elora	1,0.00	_	LOGARCENT POR		How Pioparis Elizah	1,665	0.01(0.0,121) 0.8		Nev-Hoparis Black	083,	0.80(0.41,0.88) 0.000		Non-rispenie Glack	1,000 ;		170030530300 0300	
Invitigence black				0.004		Constraine .	4,191	-	Animulanda an	0.64	Cither Hace	2,154	0.18(0.88(0.90) 0.0		Other Race 3	(154	0 29(3.59(1.02) 0.13		Contri Natio	2,094		A 2010 10 10 10 10 10 10 10 10 10 10 10 10	40
ther Race	2,104							_		0.000	Loucation			0.582	Education	1		0.532	Carterio		-		
the Race steeling	1.104					A sea dana bing and and and distance			América (60) 03		Less than high school diploma	5,219	0.96(0.82,1.11) 0.6		Less than high school diploms	210	0.82(0.50,1.35) 0.4		Loss wan righ school dploma	1.0.410	1	- www.eb(131) D.8	1.
tory reports block ther Race uselion cos thos high school diplome	1,154	-	0 7290 52 1 001 0 047			Less than high schoor diploma	1,218	-	A TRUE OF A COL. A COL.		High school diploma/equivaler	4 3 (TR)			High school distribution issues 1	.791 (0.72(9.60,1.05) 0.084		Fright survive Egitomatolganisten		1	w r (galob) 100) 0.00	
ther Race ther Race usation cas then high school diplomating ligh school diplomating-statent ploma ar atteve	1,104 ···	-	0 72(0.52,1.02) 0.047 0.67(0.46,0.98) 0.041 0.77(0.54,1.18) 0.14			Less than tigh school diploma High school diploma/squaraterit College of alterne	1,318	-	0.78(0.63(0.52) 0.007		College as always	1018	0.8/(0.75(1.00) 0.1			and the second second	a since an a set		The state of the second	1.000	1	- maga - () and () () () ()	-
Invitiophic Disck Ither Race Josefinn cas then high school diplomat ligh school diplomatiquivalent allege ar alleve scient	1,754 -	-	8 72(0.52,1.02) 0.047 8 877(0.45,0.98) 0.041 8 777(0.84,1.18) 0.18	0.958		Less than tigh school diploma High scheat diploma/weakstert Callege or above	1,318 1,321 4,545	÷	0.99(0.78,1.00) 0.007 0.99(0.78,1.00) 0.2	0.356	College or above	4.945 -	0.87(0.75,1.01) 0.0	3	Callege or above d	,945	0.57(2.43,0.77) +2.001	0.007	Maniana.		1		
on-roportic black ther Race reation cost then high school diplema gin school diplemaries, Anden diopo or allerve riage anentronabladian	4,104 -		0.72(0.52,1.00) 0.047 0.67(0.46,0.90) 0.041 0.77(0.84,1.10) 0.15	0.908		Less than tigh school optima High school optima High school optimalequivationt College or above Remission Manual optimale	1,321 1,321 4,545 4,317	-	0.99(0.082) 0.007 0.99(0.78,1.06) 0.2 0.6500 18.0.99, 0.002	0.756	College or above Marriage Marriage	4.945	0.87(0.75,1.01) 0.0	3 0.782	Callege or above d Maniage	.045	0.57(2.43,0.77) <0.001	9.887	Maniage Maniadizabababatian	4717		0.620249.0281.000	201
tor-rispone block ther Race usefun ess than high school diplome ligh school diplomaries/indent allege ar allervi ways taseedrounablation follow/files/analytion	4,104		0.72(0.52,1.00) 0.047 0.67(0.46,0.96) 0.041 0.77(0.84,1.16) 0.15 0.76(0.54,1.06) 0.15 0.96(0.64,1.06) 0.15	0.508		Less train tigh school diploma High scheal diploma/sejavatent Callege or above flamige Meniodiobeblation	1,321 1,321 4,545 4,717 1,000		0.78(0.60,0.50) 0.007 0.95(0.78,1.00) 0.0 0.65(0.78,0.99) 0.032 0.95(0.74,1.12) 0.4	0.756	College or obove Marriage Marriageotodubilation	4,945	0.81(0.751.00) 0.1	0.792 6	Callege of Above d Maniage Maniacionhabitation	.045	0.57(2.43,0.77) +0.001 0.59(2.45,0.78) +0.001	0.337	Maniage Maniadioshabitation Vikites/Manashanatation	4,717		0.6293.49,0.78) =0.0	.001
Into inspand black ther Place assilten ess then high school diplome ligh school diplometrep, instem integer teared contabilitation fictuationers treparation fictuationers treparation	2.154		072(0.52,1.00) 0.047 0.87(0.48,0.90) 0.041 0.77(0.54,1.00) 0.15 0.78(0.54,1.00) 0.15 0.88(0.42,1.00) 0.11 0.88(0.42,1.00) 0.012	0.958		Less train tigh achoor apointa High schead diplomaticplication Callogs or above Visitrage Metricol Cohobitation Hidoridivone heppention	1,321 1,321 4,545 4,717 1,590 2,667	•••	0.76(2.62,0.50) 0.007 0.99(0.78,1.06) 0.2 0.67(0.78,0.99) 0.002 0.99(0.74,1.12) 0.4 0.89(0.1.106) 0.2	0.756	College or above Marriage Marriadtochabitation Widewtikoscetespasation	4945	0.81075(10) 01 0.81075(10) 00 0.81075(10) 00 0.89072(112) 03 0.99072(112) 03	3 0.782 0	Callege & above d Marriage Manuacicobabilation 4 Widenichroneitegeration	(945	0.51/0.43,0.77) +0.001 0.59/0.46,0.79) +0.001 0.70/0.46,0.79) +0.001 0.70/0.46,1.05) 0.005	0.337	Maniage Maniedicohabitation Wilden/divorce/separation Shreamieri	4,717	-	- 0.8293.45.0.78) +0.0 - 0.8293.63.1.28) 0.4 0.8093.45.1.120 0.2	.001
Intri Egonic Ellick Her Flace Joseffon eas likes high sohool diploma jähepe er allerve mage Energetungstation ficturitikenen keganation histandisens keganation histandisens	2,004	•	0.72(0.52.1.00) 0.047 0.07(0.45.0.00) 0.041 0.77(0.64.1.10) 0.19 0.74(0.04.1.10) 0.19 0.74(0.04.1.00) 0.15 0.44(0.43.1.00) 0.11 0.66(0.43.1.00) 0.072	0.958		Less tran tign action appendent High schall diplomatequivalent Callege or above Maninge Monindiconsolvependion Unimated Line of Defents	1,318 1,321 4,545 4,717 1,000 2,057		0.76(0.002) 0.007 0.99(0.78,100) 0.2 0.67(0.78,0.99) 0.002 0.99(0.74,112) 0.4 0.69(0.01100) 0.2	0.356	College or above Manisay Manisatochabitatoe Widewitiscocetepataten Uneartind Basis of Distance	4945	0.81(0.7(1.00) 0.1 0.81(0.7(1.10) 0.0 0.81(0.7(1.10) 0.0 0.88(0.72,1.12) 0.3 0.80(0.77,1.10) 0.4	0.782	Callege or Above of Manage Manual Columbiation of Wildowidhorophagemetion of Universited	,945	0.59(2.45,0.77) +0.001 0.59(2.46,0.78) +0.001 0.70(2.46,1.05) 0.085 0.72(2.56,0.54) 0.017	988.0	Manlage Manladischabitetion Wildewickvorserbeparallen Ummented Rola of Dataetes	4,717 1,990 2,957	-	0.6290.40.0.78) +0.0 - 0.8290.63,1.28) 0.4 0.8090.66,1.10) 0.2	.001
Intri Experine Ellick Inter Flace section cas then high school diploma blogs of allows wave taxeedrowabilation ficturetionent-tegrantion ficturetionent-tegrantion ficturetionent-tegrantion ficturetionent-tegrantion ficturetionent-tegrantion ficturetionent-tegrantion ficturetionent-tegrantion ficturetionent-tegrantion ficturetionent-tegrantion	2,004 1,218 1,218 4,348 4,717 1,816 2,857 647 1,816 1,817 1,816 1,816 1,816 1,816 1,816 1,816 1,816 1,816 1,816 1,817 1,816 1,81		6 72(0.52,1.00) 0.047 6 77(0.46,0.90) 0.041 6 77(0.84,0.90) 0.041 6 77(0.84,0.90) 0.15 6 89(0.42,0.90) 0.15 6 89(0.42,0.91) 0.072 6 80(0.38,0.65) 0.5	0.958		Lets tran tign school appara High school dplomategalistent Callege or above Manage Manedicoteablation Titidourifoxeablation Ummanied Letie of Datelets Titing	1,318 1,321 4,545 4,717 1,000 2,007	+ + + + +	0.14(0.02,030) 0.007 0.94(0.78,1.00) 0.2 0.84(0.78,0.99) 0.012 0.94(0.74,1.12) 0.4 0.94(0.01,1.00) 0.2 0.94(0.01,1.00) 0.2	0.786	College or shove Manisage Maniserboundshitston Wildowsfeoroespacetien Ukreanied Ratio of Dabatese Van	4.945 4.717 1.090 2.017 4.7	0.81(0.72,1.03) 0.1 0.81(0.70,1.03) 0.0 0.81(0.70,0.040) 0.0 0.88(0.72,1.12) 0.3 0.89(0.72,1.12) 0.4 0.10(0.29,1.75) 0.6	0.792 0.091	Callege of Ablee d Maniage Maniage/Ablebiation 4 Woold/increaseperation 2 Unmenied 2 Ratio (Cloberty	.045	0.59(3.43,0.77) +0.001 0.59(3.45,0.79) +0.001 0.79(3.46,1.05) 0.005 0.72(3.56,0.54) 0.017	0.387	Maniage Maniadioshabitation Widew/drostee/separation Ummanied Ratio of Debetes Title	4,717 1,000 2,057	-	0.6203-40.078) +0.0 - 0.8203-65.128) 0.4 0.8003-66.1.120 0.2 0.8003-65.1281 0.2	1001
los responte black ther Place usellon high school diplomating, Junken sideope ne skeve wilage sakeeruuraaabadon fisawatinaa kapaadon fisawatina is of Diabotos hi b	2,754 e 1,218 e 1,201 4,948 4,917 1,916 2,957 640 7,917 		6 72(0.52,1.00) 0.047 6 77(0.46,0.90) 0.041 8 77(0.84,1.00) 0.15 8 78(0.54,1.00) 0.15 8 88(0.42,1.00) 0.15 8 88(0.42,1.00) 0.022 8 80(0.32,1.00) 0.05 8 80(0.31,1.05) 0.5	0.908	,	Less than tigh school djoisma High school djoisma/High school djoisma Dallings Namige Metrodioloobabilistion Hiddowidioconolespension Ummanied Selsi of Daloeles Nito	1,318 1,321 4,545 4,317 1,000 2,657 847 7,617	+ + + + + + + + + + + + + + + + + + + +	0.78(5.03,050) 0.007 0.99(0.78,100) 0.2 0.89(0.78,100) 0.002 0.99(0.74,1.12) 0.4 0.89(0.01,100) 0.2 0.88(0.78,100) 0.2	0.386	College or above Mannapr Mannapr Michaeldonoorsepassion Ukhaentikoorsepassion Rasis of Diatotos Yes No.	4.945 4.717 1.090 2.017 447 7.017 447	0.81(0.72(1.03) 0.1 0.81(0.72(1.01) 0.0 0.81(0.72(1.12) 0.0 0.80(0.72(1.12) 0.3 0.80(0.77(1.19) 0.6 0.03(0.77(1.19) 0.6 0.03(0.72(1.25) 0.6	0.792 0.091	Callege of Above of Matriage Matriage Widewidhonseineperation Unemented Ratio (Choldels Tes R	.045	0.59(0.45,0.79) +0.001 0.59(0.45,0.79) +0.001 0.79(0.46,0.59) 0.000 0.720.550.540 0.017 0.59(0.34,0.89) 0.002	0.397	Maniage Maniadioshabitation Vilidaw/divanoshapanilian Universited Ratia of Datates Tas No	4,717 1,000 2,057 843 7,017		0.0230.40.0.78) +0.0 - 0.0230.03.128) 0.4 0.000.06.1.12) 0.2 0.002.06.1.120 0.00 0.2202.56.0.891 0.00	001 1 1 1 1 1 1
las response black ther flace userien serien serien selice a share here a selice a share a may be about may be about the second second to a second to	4,2154 4,216 4,217 4,318 4,217 4,318 4,217 4,318 4,217 4,318 4,217 4,318 4,217 4,318 4,217 4,318 4,218 4,218 4,318 4,518 4		6 720 52.100 0.047 6 720 52.100 0.041 6 770 54.101 0.19 8 790 54.101 0.19 8 790 54.101 0.11 8 800 52.101 0.02 8 800 53.101 0.02 8 800 58.105 0.5 8 730 58.000 0.000	0.416 0.433		Less trans ligh school opporta High school opportations Callege or association Mannago Merced octobalistion Historiforono heperation Ulemanted Liste of Diabetes Ven Sa Sa of Hyperbension	1,318 1,321 4,545 4,717 1,600 2,657 847 7,617	+ + + + + + + + + + + + + + + + + + + +	0.18(0.030) 0.027 0.99(0.78,100) 0.2 0.99(0.78,100) 0.02 0.99(0.74,12) 0.4 0.99(0.74,12) 0.4 0.99(0.01.08) 0.2 0.88(0.78,100) 0.1 0.88(0.78,036) 0.025	0.356	College or above Manishpy Manishovabalantosi Walawatakoneespacation Lavaranied Ratio of Dabateos Yes No Belo of Trapeterston	4.945 4.717 1,099 2,087 947 7,017	0.81(0.24100) 0.1 0.8700751.001 0.0 0.8870751.001 0.0 0.88(0.72,112) 0.3 0.98(0.77,112) 0.4 1.03(0.70,135) 0.6 0.67(0.70,055) 0.0	0.782 0.091 0.091	Callege of above of Namige Manadoobabitation 4 Widowidhnorolaygeration 2 University of Database 3 Natio of Database 3 Natio of Database 3 Natio of Hypotension 3 Ratio of Hypotension 3	0.000 - 0.000 0.000 - 0.007 0.007 - 0.007 0.017 - 0.007	0.59(2.45,0.79) +0.001 0.59(2.45,0.79) +0.001 0.79(2.45,1.00) 0.006 0.720.550.540 0.017 0.59(2.34,0.01) 0.002 0.69(2.37,0.89) +0.002	0.337	Maniage Manipolicohabitation Vitidan/divorcohapanellion Unrevented Ratio of Dathetas Tas Nai Ratio of Hypertanalon	4,717 1,090 2,057 847 7,017	÷	0.6292.40.078) =0.0 - 0.8292.63.128) 0.4 0.8090.66.1192 0.2 0.6892.43.108) 0.08 0.7292.56.089 0.00	(001 1 1 03
las respond black ther flace scellen estellen tigh school djoorwalvy, Juden dange er alleve ways ways ways ways ways and diskertionate hegestellen tidswittionate hegestellen tidswitti	2,754 = 1218		072032.100 0.047 04700.40.080 0.041 07700.40.100 0.15 04000.41.100 0.15 04000.41.000 0.15 04000.41.000 0.15 04000.41.000 0.02 04000.81.000 0.02 03000.81.04 0.6	0.908 0.416 0.903		Less Trans ligh school opporta High school opportageaution Callings or above Harringo Marced obselfactors Hillocondiscono begenetion Unemarted Unemarted Unemarted Unemarted Sets of Dubbeles Wes Less de la constante Less de la con	1,318 1,301 4,546 4,717 1,000 2,057 847 7,017	+ + + + + + +	a Hijo 60,030) 4 007 a 99(0 78,100) 42 0.09(0 78,100) 42 0.09(0 74,112) 44 0.09(0 01,100) 42 0.88(0 78,040) 4002 0.88(0 78,040) 4003 0.88(0 78,040) 4003 0.88(0 72,10) 4043	0.356 0.332 0.547	College for shore Marriage Karriadhohalinaton Wahardisonening anslan Universitä Rasis of Dabatos Yes No Relies of hypotension Yes	4.945 4.717 1,090 2,017 847 7,017 1,090	0.87075.100 07 0.87075.100 00 0.87075.100 00 0.87077.110 0.8 0.80077.110 0.8 1.000771.100 0.8 0.87075.050 0.0	0.091 0.001 0.043	Callege or show or Marriago Marriago M	0.05	0.5193.43,0.77 + 48.07 0.59(3.45,0.79) + 88.07 0.72(3.46,1.09) 0.086 0.72(3.46,1.09) 0.087 0.59(3.46,0.79) 0.082 0.99(3.46,0.79) 0.082 0.59(3.46,0.79) 0.082	0.387	Manipe Maniphobabilision Virdenkonzelepenniken Unrenied Rate of Datetes Task Na Rate of Hypertansion Yas	4,717 (.000 2,057 847 7,017 1,000		0.0324.00.78) +0.0 0.0220.031.128) 0.4 0.000.061.193) 0.2 0.000.061.193) 0.2 0.000.061.193) 0.00 0.2222.56(.0.89) 0.00 0.0320.46(.0.87) 0.00	85 83 90
las response black ther flace userion serion serion serion deponation, haden ishop or deve resp resp taseet/constants taseet/constants taseet/ to of Chapterson tase to of hisportonion tase to to	2,254 = 1218		6 7200.52.1.00 0.047 6 8770.44.0.90 0.041 8 770.84.1.10 0.19 8 790.54.1.10 0.19 8 890.42.1.00 0.11 8 890.42.1.01 0.072 8 800.58.1.01 0.072 8 800.58.1.01 0.000 8 870.55.0.00 0.000 8 8970.55.0.07 0.000	0.908 0.416 0.903	,	Less trans tign school opponta High school oppontagealader Calligor or above Merrodo Ontobalsion Historeforce begenster Unsersted Unserside Unserside State of Expediences Take	1,318 1,321 4,546 4,717 1,000 2,857 847 7,017 1,880 0,001	+ + + + + + + + + + + + + + + + + + + +	a.Hg.63,050, 602 1990,78,100, 02 1990,78,100, 02 1990,74,112, 04 0090,01,00, 02 0490,01,00, 02 0490,71,00, 01 0490,71,00, 0.003 0490,72,10, 0.01 0490,72,10, 0.01	0.356 0.352 0.847	College or othere Maninger Maninger Maninger Maninger Maninger Rate of Dassets Van No Rate of Dassets No Rate of Hypertension Yes Ho	4.945 4.717 1.080 2.087 347 7.017 1.080 4.7177 4.7177 4.7177 4.7177 4.7177 4.717	0.8/07/31.00 0.0 0.8/07/21.00 0.0 0.8/07/21.12 0.3 0.8/07/21.12 0.3 0.8/07/21.12 0.4 0.8/07/21.130 0.4 0.0/07/20.050 0.0 0.0/07/20.050 0.0	0.792 0.001 0.001 0.143	Callege of above of Maninge Maninge Maninge Maninge Maninge Maninger (1999) of Weight Maninger (1999) of Maninger (1999) o	045	0.5793.43,0.779 +8.001 0.59(0.45,0.70) +8.001 0.70(0.46,1.00) 0.000 0.7293.56,0.590 0.001 0.59(0.30,0.89) 0.002 0.89(0.37,0.89) +8.001 0.59(0.40,0.73) 0.002 0.72(0.90,880 0.003)	0.597 0.788 0.399	Maniage Maniadiobabatalan Viliden/divorce/separation Unrearried Pasia of Distantes Na Pasia of Hypertansion Yos Na	4,717 (.000 2,957 847 7,017 1,860 6,004		0.622(3.45),078) •0.0 0.622(3.5),128) 0.4 0.890(36(1.15) 0.2 0.890(36(1.15) 0.2 0.890(36(1.15) 0.2 0.22(0.5),089) 0.00 0.22(0.5),087) 0.00 0.22(0.5),059) 0.00	1001 1 105 03 30 30
las response billion ther Place usedion seelion tigh school dysomalogusteen sights and dysomalogusteen singer at show ways ways ways ways ways ways ways way	4,754 4,218 4,217 4,348 4,777 1,040 5,057 7,017 1,060 6,094 		6 720352.100 0.047 68700.46.080 0.041 87700.46.180 0.19 87700.46.180 0.19 87800.45.100 0.19 88800.42.041 0.012 88800.42.041 0.022 8800.45.041 0.05 87300.58.040 0.000 88900.65.1341 0.6 88700.52.047 0.003	0.998		Less Trans tign school opporta High school opportagesited Callings or above Hernolitooteabasten Hildowideoteab	1,318 1,321 4,546 4,717 1,000 2,057 847 7,017 1,000 0,001	+ + + + + + + + + + + + + + + + + + + +	a.Hijo.63,050, 40,017 a.9Hij0.78,059, 40,02 4.9Hij0.78,059, 40,02 4.9Hij0.78,150, 40,02 4.9Hij0.78,150, 41 4.8Hij0.78,050, 41 4.8Hij0.78,050, 40,023 4.8Hij0.78,050, 40,023 4.8Hij0.78,050, 40,028 4.8Hij0.78,050, 40,028	0.395 0.392 0.847	College or extern Markey Markey Markendoutstanden Wahrdinschertingsatten Marke Yes No Reite of Hypotensien Yes No Reite of Hypotensien Yes	4393 4717 1,090 2,097 447 7,017 460 4,004 4,004	0.8/07/01.000 0.1 0.8/07/01.000 0.0 0.8/07/01.000 0.0 0.8/07/01.000 0.0 0.8/07/01.000 0.0 0.8/07/01.000 0.0 0.8/07/01.000 0.0 0.8/07/01.000 0.0	0.792 0.091 0.143 6 0.175	Callege of Allowing Managed Charles Waterschoolshapper and Unwested Ratio of Objekter Nei Ratio of Hippetension Yes Ratio of Hippetension Ratio of Hippetension	0.025 0.000 0.007 0.017 0.010 0.000 0.000	0.5793.43,0.779 +8.001 0.59(0.46,0.79) +8.001 0.79(0.46,0.59) 0.001 0.7930.560.590 0.001 0.69(0.34,0.87) 0.002 0.89(0.357,0.89) +8.001 0.59(0.40,0.79) 0.002 0.79(0.40,0.79) 0.002	0.397	Manippe Manipolohabatelen Videndikoseehepantilen Ummerind Ratis of Datestes Na Ratis of Hyperanalos Yos No Na Ratis of Hyperanalos No Ratis of Hulgerancy	4,717 1,990 2,957 847 7,017 1,800 6,004		0.029.40,079 -0.0 -0.029.031.289 0.4 0.000.061.109 0.2 0.000.061.109 0.20 0.0293.56,0.899 0.00 0.0293.66,0.879 0.00 0.0293.61,0.039 0.00	001 4 1 03 03 05 35
lary-inspire black ther filese scalars in the filese scalars in the filese scalars in the filese scalars in the filese scalars in the filese scalars in the filese is a in the filese is a file is a fi	2,754 = (218)	· · · · · · · · · · · · · · · · · · ·	0.72(0.52.1.00) 0.047 0.87(0.46.0.90) 0.041 0.77(0.04.1.00) 0.15 0.79(0.04.1.00) 0.15 0.09(0.42.1.00) 0.11 0.09(0.42.1.00) 0.012 0.00(0.1.04) 0.002 0.00(0.04.00) 0.000 0.09(0.06.1.04) 0.06 0.87(0.06.0.07) 0.003 0.89(0.06.1.04) 0.06 0.89(0.06.1.04) 0.06	0.958 0.416 0.953 0.056		Less than light statuct append light schurt afformative Uniting on tables Mannedon between Mannedon between Versammer Versammer Na Na Status of typedevision Table Status of typedevision Table Status of ty	1,318 1,321 4,546 4,717 1,000 2,057 847 7,017 1,000 0,004 2,004	+ + + + + + + + + + + + + + + + + + + +	a.rep.a.a.se, a.so, a.co, a.so, a.so, a.so, a.co, a.so	0.356 0.352 0.847 0.585	Colling or entore Marking Mark	4.945 4.777 1.099 2.017 	0.000/2.1100 0.0 0.000/2.1100 0.0 0.000/2.1100 0.0 0.000/2.1100 0.0 0.000/2.1100 0.0 0.000/2.100 0.0 0.000/2.00.000 0.0 0.000/2.1100 0.0 0.000/2.1100 0.0 0.000/2.1100 0.0	0.792 0.091 0.091 0.143 6 0.0076	Callage of Allow C Manage Man	045	63/1243(677) 48/07 65/0246679 48/07 67/0246760 67/0246679 67/024679 65/0246679 65/0246679 65/02479 65/024679 65/	0.397 0.789 0.295 0.423	Maningo Manindoshabilition Vilden-disorce/sepantion Unmented Rota of Duklens Tak Rota of Duklens Na Rota of Hispaney, Tak	4,717 1,990 2,957 843 7,017 1,860 6,004 333	+ + + + + + + + + + + + + + + + + + + +	6.829.46.0.89 -0.0 6.8290.551.28 0.4 6.8290.651.180 0.2 6.8890.43,100 0.00 6.7292.56,0.89 0.00 6.6393.46,0.87 0.00 6.7593.61.0.53 0.00 6.8793.46,0.80 0.00	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
on-Happing DataContent Face Inter Face scales as then high school dypomategulated interpret and a school dypomategulated	2,254 = (2)8 = (2)8 		8720052.100 0.047 8770.46.080 0.041 8770.46.080 0.041 8770.46.100 0.15 8780.42.100 0.15 8880.42.100 0.15 8880.42.100 0.05 8800.42.100 0.000 8890.40.00 0.000 8870.82.087 0.080 1890.86.422 0.16	0.998 0.416 0.903 0.903	,	Less than light school époinn light school époinne light school époinne Manedeolosabation Manedeolosabation Umanedo Tillionerférondesembri Umanedo Tillionerférondesembri Tillionerférondesembri Tillioner Tillionerférondesembri Tillioner Till	1,321 1,321 4,545 4,717 1,000 2,057 847 7,617 1,860 6,004 503 7,521	+ + + + + + + + + + + + + + + + + + + +	Arigo 60,050,0 4002 A090,071,000,02 A090,071,000,02 A090,071,000,02 A090,071,000,02 A090,071,000,02 A090,071,000,02 A090,071,000,02 A090,071,000,02 A090,071,000,020 A090,071,000,000 A090,070,000,000 A090,070,000,000 A090,000,000	0.799 0.792 0.847 0.993	College or observ Lansachushatharian tons-achushatharian tons-achushatharian Pasa of Datatos Yas No No No No No No No No No No	4.945 4.717 1.095 2.057 4.7 7.917 4.605 4.004 4.004 4.7 7.917 4.005 4.004 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.	astrop 20,000 astrop 20,0	0,792 0,009 0,009 0,045 0 0,045 0,0475	Cubige of Johney C Marriego (Marriego (Wolgowich creating particular) Universitied Wolgowich (Regional (Re	0.05 0.00 0.07 0.07 0.08 0.08 0.08 0.08 0.09	0.5193.43,0.77 + 48.07 0.59(3.45,0.79) + 48.07 0.79(3.45,0.79) + 48.07 0.79(3.45,0.59) 0.007 0.59(3.34,0.47) 0.002 0.89(3.37,0.89) + 88.07 0.59(3.40,0.79) 0.002 0.79(3.90,0.89) 0.003 0.43(3.31,110) 0.101 0.43(3.33,1.110) 0.101	0.537 0.789 0.895 0.623	Manigo Manidobabbiliston Welandibusehepanition Ummernie Ratu of Dahetas Mai Asta of Hypersmalos Yas No No Ratu of Malignamy Yas No	4,717 1,000 2,057 840 7,017 1,800 6,004 333 7,531	++++++	6 4293.490.789 -0.0 6 4292.690.71.289 0.44 0 4000.681.199 0.22 0 4000.681.199 0.20 0 4000.460.879 0.00 0 4792.660.879 0.00 0 4792.660.879 0.00 0 4792.660.879 0.00 0 4792.660.879 0.00	4 1 385 383 06 05 34 32
Invincione tancie tanci	2,754 = (2)15 = (12)15 		0.7293.22.1001 0.047 0.87294.0.001 0.041 0.77294.0.101 0.041 0.77294.0.101 0.041 0.79094.0.1001 0.012 0.8909.0.21.041 0.012 0.8909.0.21.041 0.012 0.8909.0.21.041 0.002 0.8909.021.041 0.002 0.8909.021.041 0.002	0.904 0.416 0.903 0.056 0.702		Less than light school époinn Type school époinne Unitarie or alcon Marcedotabablistion Marcedotabablistion Unitaried Titles of Clandes The Status of Epointenion The Status of Epointenion The Status of Epointenion The Status of Epointenion The Status of Epointenion Status of Epointenion Status of Epointenion Status of Epointenion Status of Epointenion	1,321 1,321 4,545 4,717 1,000 2,057 847 7,617 1,860 0,001 503 7,521	1 · · · · · · · ·	a Hig 66,050, 40,07 40,97,07,0,00, 42 40,97,07,0,00, 42 40,97,07,0,00, 40 40,97,07,0,00, 40 40,97,07,0,00, 40 40,97,07,0,00, 40 40,97,0,00, 40 40,92,0,00, 40 40,92,0,00, 40 40,92,0,00, 40 40,92,0,00, 40 40,92,0,00, 40 40,95,0,00, 40 40,95,00,00, 40 40,95,00,00, 40 40,95,00,00,00,00,00,00,00,00,00,00,00,00,00	0.796 0.792 0.847 0.845	College or obbor Manipublishing Manipublishi	4.945	astrop20,1100 00 astrop20,040 00 astrop21,110 04 astrop21,110 astrop21,1	0.392 0.091 0.001 0.045 0.045 0.045 0.045 0.045	Callage of Jakes Managabothabitistion Managabothabitistion Uternetwood Radua Official Radua Offi	.005	6.893.430,079 +0.893 6.990.450,799 +0.897 0.790.450,090 0.006 0.7293.950,090 0.007 0.8903.34,049 +0.007 0.9904.400,790 0.002 0.7393.950,049 0.003 0.7393.950,049 0.003 0.002 0.002,000 0.002 0.002,000 0.002 0.002,0000 0.002,000 0.002,00000	0.557	Maninge Menindershebiten Widenförsreihegenrifen Ummereih Retar of Datelles Teis Na Retar of Hypertrasion Na Retar of Melgenny, Teis Na Retar of Melgenny, Teis Na Retar of Melgenny,	4,717 1,090 2,997 847 7,917 1,860 6,004 333 7,531	+++++++++++++++++++++++++++++++++++++++	0.020.46.739 - 40 0.020.05.739 - 64 0.020.05.139 - 04 0.000.08.139 - 02 0.020.05.109 - 020 0.020.06.089 - 020 0.020.05.000 0.020.05.000 0.000 0.020.05.000 0.0000 0.00000 0.00000 0.0000 0.000000 0.00000 0.000000 0.0000	001 4 1 385 303 06 05 05 05
Invitional back invitional backs controls c	2,754 = 1218 = 1218 		8/29/32.109 0.047 8/79/40.09 0.041 8/79/40.09 0.041 8/79/40.119 0.19 8/80/42.109 0.11 8/80/42.109 0.11 8/80/42.109 0.11 8/80/42.109 0.11 8/80/42.109 0.01 8/80/40.109 0.000 8/80/40.104 0.000 8/80/40.1041 0.000 8/80/34.038 0.000	0.909 0.416 0.903 0.005 0.700		Less than light school épotens light school épotens light school épotens Marced écolobabilition Ummardie Marced écolobabilition Ummarde Tille of Elabeles Na Kan d'Halpsales Na Call dagsaaley Na Sina d'Alapsaley Na Sina d'Alapsaley Na Sina d'Alapsaley Na Sina d'Alapsaley Na Sina d'Alapsaley	1,318 1,321 4,546 4,317 1,000 2,057 847 7,017 1,800 6,004 233 7,521 6,193	1 · · · · · · · ·	Arrigola (also) dorr Arrigola (als	0.396 0.392 0.847 0.868 0.456	College or obbee Kansaya Kansayabahabahabahabahabahabahabahabahabahab	4.945 4.777 1.099 2.037 	astrop.21,100 a0 astrop.20,049 a0 astrop.20,049 a0 astrop.21,120 a0 astrop.21,20 a0 astrop.21,20 a0 astrop.21,20 a0 astrop.21,20 a0 astrop.21,20 a	0.792 0.091 0.045 6 0.045 6 0.045	Callege of Johns Manuschothaltadan Manuschothaltadan Chevernol Robotik	0.05	8.879.8.80.779 (-8.897 8.969.450.779 (-8.897 9.709.6450.6006 8.729.550.640 0.077 8.869.340.640 0.077 8.869.340.640 0.075 8.959.400.750 0.082 8.739.950.680 0.083 8.869.331.130 0.14 8.869.331.130 0.14 8.869.331.50 0.140	0.337 0.788 0.689 0.609	Manifop Manifoldshabition Wellenderschabition Unterented Tell Tell Tell No No No No No No No No No No No No No	4,717 1,090 2,957 843 7,917 1,860 6,004 333 7,831 4,193		0.000,06,039, -40, 0.000,06,130, 04, 0.000,06,130, 02, 0.000,06,130, 020, 0.000,06,030, 000, 0.000,06,030, 000,000, 0.000,06,030,000,000,000,000,000,000,000,0	001 4 1 385 303 005 005 005 005 005 005 005 005 00
In-Higher Back Inter These cases have have a set of a second and cases have a second and a second and all second a second and a second and a second and a second a second and a second a second a second and is a second a second and a second a second a second a second a second a second a second a second a second a second a second a second a second a second a second a second a second a second a second a se	2,754 1,218 1,218 1,217 1,210 2,252 507 1,010 1,000		8 729122.1001 0.007 8 87794.001 0.041 8 77904.1101 0.19 8 77904.1101 0.19 8 8890.42,1001 0.12 8 8890.42,1001 0.12 8 8890.34,1001 0.12 8 8890.34,1001 0.02 8 8900.34,1001 0.02 8 8900.34,1001 0.000 8 8900.34,1001 0.000 1 8890.84,420 0.000 1 8900.84,420 0.000 1 8900.84,400 1 8900.84,4000 1 8900.84,400 1 8900.84	0.994 0.416 0.903 0.905 0.905		Less Pur lags soloci époines l'ags soloci a gonnes lesses l'agne cha a gonnes lesses l'agne de la construcción de la constru- listenes d'antes de la construcción l'agne d'antes de la construcción l'agne de la construcción de la constru- tes de la construcción de la constru- tes de la construcción de la constru- la construcción de la construcción la construcción de	1,318 1,321 4,546 4,717 1,600 2,657 847 7,617 1,860 6,004 933 7,521 6,123 1,871	+ + + + + + + +	Arabida (a) (a) (a) (a) Arabida (a) (a) Arabida Arabida (a) Arabida A	0.786 0.782 0.847 0.545	College or observed Densings Density of the second second second Density of the second second second second Particle of Diabetes West Particle of Diabetes Not Particle of Second Second Second Particle of Second Second Second Second Second Particle of Second Second Second Second Second Second Particle of Second	4.945 4.777 1.089 2.017 4.77 7.917 4.0000 4.0000 4.0000 4.0000 4.0000 4.0000 4.0000 4.0000 4.	astrophics (100) 60 a	0.091 0.091 0.045 0.045 0.045 0.045 0.045 0.045 0.045	Callege or Johnson MassacyColobalisation / MassacyColobalisation / MassacyColobalisation / Realised Colobalises / Network / Colobalises / Network / Network / Network / Network / Network / Network /	(045)	8.879.630,079, 18.807 8.399.65,079, 18.807 8.399.65,079, 18.807 8.399.65,049, 0.007 8.399.60,049, 0.002 8.399.60,079, 0.002 8.399.60,079, 0.002 8.399.60,079, 0.003 8.399.60,079, 0.003 8.499.301,180,014 8.499.52,0.79, 48.97 8.499.52,0.79, 48.97 8.499.52,0.59,0.007 8.499.52,0.007 8.499.5	0.397 0.786 0.423 0.669	Mintipo Mandodovobilistim Willowichosobilistim Umened Kasa d'Jabeles Yak Na Kasa d'Ispennaio Yas Na Reis d'Asignancy Yas Na Reis d'Asignancy Yas Na Reis d'Asignancy Yas Na Na	4,717 1,090 2,097 8,097 1,850 6,004 333 7,531 4,993 1,871	++++++	0.020.46.239 - 40. 0.020.05.239 - 0.4 0.020.05.139 - 0.4 0.020.05.139 - 0.2 0.020.05.139 - 0.2 0.020.05.059 - 0.00 0.020.05.059 - 0.00 0.020.050 - 0.05 0.050.050 - 0.050.05 0.050.050 - 0.050.05 0.050.050 - 0.050.05 0.050.050 - 0.050.05 0.050.050 - 0.050.05 0.050.050 - 0.050.05 0.050.050 - 0.050.05 0.050.050.05 0.050.050 - 0.050.05 0.050.050.05 0.050.050.05 0.050.050.05 0.050.050.05 0.050.050.05 0.050.050.050.05 0.050.050.050.05 0.050.050.050.050.05 0.050.050.050.050.050.050 0.050.050.050.050.050.050.050.050 0.050.050.050.050.050.050.050.050.050.0	001 4 7 385 385 385 385 385 385 385 385 385 385
In-rispons Back Invertibut cash ban holp a bold diploma sash ban holp a bold shipp a maker sasarigan Basarigan balangan Basarigan Basar	1.754		8 729122.1001 0.047 847794.001 0.041 847794.001 0.041 8 4490.341.049 0.041 8 4490.341.049 0.15 8 4490.341.049 0.15 8 4490.341.049 0.05 8 4590.341.340 0.05 8 4590.341.340 0.05 8 4590.341.341 0.05 8 4490.341.342 0.16 8 4490.341.342 0.16 8 4490.341.342 0.16 8 4490.341.342 0.01	0.998 0.416 0.903 0.905 0.702		Less Twin Kign school opportune Types school opportune/securited Callego or above Mithendiformahapsandon Mithendiformahapsandon Mithendiformahapsandon Ness Mithendiformahapsandon Ness Mithendiformahapsandon Ness Mithendiformahapsandon Ness Mithendiformahapsandon Ness Mithendiformahapsandon Ness	1,311 1,321 4,546 4,546 4,717 1,000 2,057 847 7,017 1,860 6,004 233 7,521 6,123 1,071	1 · · · · · · · · · · ·	8 HIG 64,000 607 999(17),100 92 607 899(17),100 92 607 899(17),100 92 899(17),100 92 899(17),100 92 899(17),100 91 899(17),101 92 899(17),100 91 899(17),100 91 899(17),000 100 809(17),000 100 809(17),000 100 809(17),000 100 809(17),000 100 809(17),000 100 809(17),000 100 809(17),000 800(17),000 80	0.356 0.372 0.567 0.456 0.455	College or observed Licensey Watherdoncementation Watherdoncementation United of Datasets Yes National Characteristics Yes National Characteristics Yes National Characteristics National Characteri	4.945 4.777 1.099 2.007 4.777 7.097 4.77 7.017 4.600 4.6	align 2,1100 at 100 at 10	0.792 0.091 0.045 6 0.045 6 0.045 2 7 0.541 7 0.558	Callege or Johnson Marinegi or Johnson Marinegi obschedenister Marinegi obschedenister Marine of Dispotenterion Redux Of Dispo	(845) (717) (807) (907) (907) (908) (909) (900) (900) (900) (900) (901) (902) (903) (913) (913)	8.893.630,079, 48.893 8.998.450,799, 48.893 9.298.645,0790, 48.893 8.298.540,849, 0.097 8.898.540,849, 0.097 8.898.540,849, 0.093 8.898.440,790, 0.082 8.739.890,849, 0.083 8.888.510,770, 48.893 8.889.51,770, 48.893 8.898.51,677, 48.893 8.899.51,677, 48.893 8.899,677,678,788 8.899,678,797,798 8.899,678,797,798 8.899,798 8.899,798 8.899,798 8.999,799 8.999,799 8.999,799 8.999,799 8.999,799 8.999,799 8.99	0.597	Managa Managaban bahalian Walawa Anakasa Kanaga Kanaga Kanaga Managa Managa Managa Managa Kan	4,717 1,090 2,097 8,07 7,017 1,000 6,004 333 7,531 4,192 1,071	+ + + + + + + + + + + + + + +	0.020.46.239 - 40. 0.020.05.239 - 64. 0.020.05.139 - 04. 0.020.05.130 - 02. 0.020.05.130 - 02. 0.020.46.039 - 000. 0.020.46.039 - 000.000. 0.020.46.00000 - 000.00000000000000000000000000	(001 4 7 385 305 05 05 04 42 22
owneighter Black working cash han kigh school diporter school diporter school diporter school diporter School diporter o di diporter school diporter school disparse school di	1.254		8/2012/1091 0047 8/7704/109 0047 8/7704/109 019 9/704/109 019 9/704/109 019 9/8004/1091 019 9/8004/1091 019 9/8004/1091 019 8/8004/1091 0049 8/8004/1091 0049 18/8004/1091 0049 18/8004/1091 0049 18/8004/1091 019	0.998 0.416 0.903 0.095		Less Para lign school dipotent physic school dipotent Camping Marcel School School Million Holmon School Million Holmon School Less of Labertes Na School Camping Na School Ca	1,321 1,321 4,546 4,546 4,717 1,000 2,007 847 7,017 1,860 0,004 333 7,521 6,123 1,671 6,128	+ + + + + + + + + + +	Aligologicality dogr Direction (1990) Aligologicality (1990)	0.356 0.332 0.847 0.955 0.456 0.887	College or oblow Exercised Collections Research and Collections Research and Collections Vision of Diabetes Vision Passe of Plagetersian Vision Research and Anny and National Annual Annual Vision Research and Annual Research and Annual Vision Research and Annual Research and Annual Res	4.945	datago 2,1 100 0 datago 2,1 000 0 data	0.792 0.001 0.001 0.045 0.045 2 0.045 7 0.558	Calego es Johns Martingo Withoushouther and Withoushouther and Withoushouther and Withoushouther Reads of Langeaners Reads of	(045)	6.3476.436,0779 (1807) 6.3068.456,0739 (1807) 6.2068.456,0739 (1807) 6.2068.456,0749 (1907) 6.3068.346,849 (1907) 6.3068.346,849 (1907) 6.3068.346,849 (1907) 6.3068.456,0739 (1906) 6.3068.456,0739 (1906) 6.3068.450,0739 (1906) 6.3068.450,0739 (1906)	0.397 0.788 0.423 0.669 0.182	Managa Managabab darilin Walando kowab kapanilan U warando Maraka Maraka Rata da Kabana Rata da Kabanany Na Rata da Malayanay Yan Rata da Malayanay Yan Rata da Malayanay Na Rata da Malayanay Na Rata da Malayanay Rata da Malayana	4,717 1,090 2,097 843 7,017 1,000 6,004 333 7,531 6,193 1,871 4,799		0.020-06.239 -040 0.020-06.239 -040 0.020-06.139 -02 0.020-06.039 -000 0.020-06.087 -	001 4 2 385 385 300 105 005 005 005 005 005 005 005 005 0
Invitations Back Invitations Back assistant back about displants assistant back about displants assistant assi	1254		8 220122.1001 0.047 847294.001 0.041 847294.001 0.041 8 2709.41.101 0.15 8 2005.81.1001 0.15 8 2005.81.1001 0.15 8 2005.81.1001 0.05 8 2705.20.201 0.05 8 2705.20.201 0.05 8 2005.81.101 0.05 8 2005.81.101000000000000000000000000000000	0.998 0.416 0.903 0.905 0.905		Less nes lagos stoco deposi- legas canta diposocialismo. Enlingo e alcono de la cono de la conode la cono de la conode la cono de la cono de la	1,318 1,321 4,546 4,717 1,000 2,057 847 7,617 1,860 0,054 333 7,551 0,183 1,871 0,188 1,364	+++++++++++++++++++++++++++++++++++++++	Arapida (also) 4 007 Arapida (also) 4 07 Arapida (also) 4 0	0.386 0.372 0.867 0.880 0.496	College or observed barrenspir and second second second with the observed second second barrenspir Nation of Diseases Yes National of Integration second National of Integration National of Integration National of Accelerated direktion National National of Accelerated direktion National Nati	4.945	0.08(9)/21.00(9) (1) 0.08(9)/21.00(9) (2) 0.08(9)/21.10(9) (2) 0.08(9)/21.11(9) (2) 0.08(9)/21.11(9) (2) 0.08(9)/21.01(9) (2)	5 6 0.792 0.001 0 0.001 0 0.001 0 0.001 0 0.001 0 0.001 0 0.001 0 0.001 0 0.001 0 0 0 0 0 0 0 0 0 0 0 0 0	Callege or Johnson MassacyColondonStrome of MassacyColondonStrome of MassacyColondonStrome of MassacyColondonse Reads of Chapters and Reads of Chapters an	(843 (717 (807 (807 (803 (804) (804) (804) (804) (804) (804) (805) (806) (807) (808) (809) (800) (801) (802) (803) (804)	8 3494 55,079 4 58,079 4 58,07 8 3938 45,079 4 58,07 8 3938 45,079 4 58,07 8 3938 35,050,640 50,077 8 3493 32,050,640 50,002 8 3493 35,040 4 58,07 8 3493 35,040 4 58,07 8 3493 35,040 4 58,07 8 3493 35,040 4 59,07 8 3493 35,040 50,007 8 3493 35,000 50,007 8 3493 36,000 50,007 8 3493 46,000 51 8 3494 46,000 41 1 4 14 14 14 14 14 14 14 14 14 14 14 14	0.397 0.788 0.096 0.423 0.669 0.182	Managan Managan Sanagan Sanaga	4,717 1,990 2,997 847 7,917 1,850 6,994 333 7,831 4,990 1,844		0.020-06.239 -040 0.020005(1.02) 02 0.020005(1.02) 02 0.020005(1.02) 02 0.020005(1.02) 02 0.020005(1.02) 02 0.020005(1.02) 02 0.020005(1.02) 02 0.02005(1.02) 02 0.02	001 4 2 385 385 300 305 305 402 402 402 32 3
on rigono Back on rigono Back cashan backata dipensi sashan backata	2.554		8 2293.22.1081 0.047 8 8779.43.1081 0.041 8 8779.43.1081 0.041 8 8789.43.1081 0.01 8 8789.43.1081 0.01 8 8789.43.1081 0.01 8 8789.43.1081 0.01 8 8789.43.1081 0.000 8 8799.43.1081 0.000 8 8799.43.1081 0.000 8 8799.43.1081 0.000 8 8799.43.1081 0.000 8 7299.44.1081 0.000 8 7299.44.1081 0.000 8 7299.44.1081 0.000	0.998 0.416 0.953 0.955		Less trans ligns shoot pages ligns schart dynomicsellen Enligins schart dynomicsellen Michael Schart (1998) Michael Schart (1998) Liener Schart (1998) Namer Schart (1	1,318 1,321 4,546 4,516 1,000 2,057 1,000 0,001 533 7,521 6,183 1,321 6,189 1,344 1,321		http://di.com/di.com/ http://di.com/di.com/ http://di.com/di.com/ http://di.com/	0.356 0.332 0.547 0.555 0.456 0.557	Origen or advoc Genergy Webselfsonsenspaces Webselfsonsenspaces Haus of Database National States National Stat	4.945	0.0007/0.000 0.00077/1.000 0.00077/1.000 0.00077/1.000 0.00077/1.000 0.00077/1.000 0.00077/1.000 0.00077/0.0007 0.00077/0.00077 0.000	5 0.732 0.001 9 0.145 6 0.875 2 7 0.561 7 0.356	Cange at allow of the state of	(005)	8.393.45(-77) - 48.07 8.593.45(-163) - 0.697 8.793.45(-163) - 0.697 8.793.45(-163) - 0.697 8.793.45(-163) - 0.697 8.493.33(-164) - 0.697 8.493.33(-164) - 0.697 8.493.45(-77) - 0.697 8.493.65(-77) - 0.697 8.493.65(-77) - 0.897 8.493.65(-77) - 0.897 8.493.65 8.495.65 8.495.65 8.495.65 8.495.65 8.495.65 8.495.65 8.495.65 8.495.65	0.397 0.788 0.609 0.102	Managa Managaban bahalan Watan donorah bahalan Watan donorah yapan talan Managaban Watan Nasa di Japana ya Nasa Nasa di Japana di Jahang Managabang Managa	4,717 (1990 2,957 8,67 7,917 1,860 6,904 333 7,531 4,790 1,344 1,221		6 000-06.078) - 40 6 000-06.179 - 62 6 000-06.179 - 62 6 000-06.179 - 62 6 000-06.087 - 600 6 000-060 6 000-000-060 6 000-060 6 000-060 6 000-060 6 000-060 6 000-000-000 6 000-000-000 6 000-000-000 6 000-000-000 6 000-000-000 6 000-000-000 6 000-000-000 6 000-000-000 6 000-000-000-000 6 000-000-000-000 6 000-000-000-000 6 000-000-0000 6 000-000-000-0000 6 000-000-000-0000 6 000-000-0	4 2 385 385 385 385 485 485 485 485 485 485 485 485 485 4
or response black or response black cases blan helps abold dipolar provide dipolar dipolar provide dipolar devel response black dipolar dipolar so di cabatos di caba	1254		8 7293.22.1001 0.047 8 8779.43.001 0.047 8 8779.43.1001 0.13 8 8890.42.1001 0.13 8 8890.42.1001 0.13 8 8890.42.1001 0.002 8 8890.42.1001 0.002 8 8890.42.1001 0.002 8 8900.42.1001 0.002 8 1000.42.1001 0.002 8 1000.4000000000000000000000000000000000	0.998 0.416 0.903 0.905 0.905	, , , ,	Las tan lage stabol pages page stabol dynomycelliadd They instab dynomycelliadd Wendyn	1,318 1,301 4,546 4,717 1,000 2,057 847 7,017 1,000 0,000 533 7,521 0,100 1,000 0,100 1,000 1,001 0,100 1,001		High angle and a graph of the second se	0.386 0.392 0.867 0.580 0.456 0.887	Origing or school De langing Withour School School De School School School School School De School School School School School De School Sch	4.945	0.000/02.1100 00 0.000/02.1100 00 0.000/02.1000 00 0.0000/02.1000 00 0.0000/02.1000 00 0.0000/02.100000000000000000000000000000	5 0.732 0.001 5 0.145 6 0.475 6 0.475 7 0.586 0.586	Compare Jane (Compare Jane) Janing (Compare Jane) University of Control (Compare Jane) University of Control (Compare Jane) National Association Compare Jane) National Association National Associati	(100) (177 (000) (001) (001) (001) (001) (001) (001) (001) (001) (001) (001) (001) (01) (02) 1	6.379.04,0.277, -4.897 1.590,-45,0.29, -4.807 1.590,-45,0.29, -4.807 1.590,-45,10, -0.66 1.590,-50,0.504, -4.897 1.690,-34,0.890, -0.897 1.690,-34,0.299, -0.89 1.690,-0.299, -0.89 1.690,-0.299,-0.89 1.690,-0.299,-0.299,-0.29 1.690,-0.299,-0.29 1.690,-0.299,-0.29 1.690,-0.299,-0.29 1.690,-0.299,-0.299,-0.29 1.690,-0.299,-0	0.337 0.198 0.695 0.433 0.669 0.182	Managan Managan Managan Mayan Mayan Managan Mayan Managan Nanagan Man	4,717 (.090 2,957 1,850 6,004 6,004 333 7,331 4,798 1,344 1,221 0,0	+++++++++++++++++++++++++++++++++++++++	6 450 - 450 - 350 - 350 - 450	4 2 385 385 305 305 402 402 3 5
Non-Happin Block Joseffer Leas Ban Happ Andred Argebreit Selection Leas Ban Happ Andred Argebreit Selection Selecti	2.54		8 72932.1.001 0.047 8 87794.4.001 0.041 8 8794.8.001 0.041 8 7895.8.1001 0.01 8 8896.8.1.001 0.01 8 8896.8.1.001 0.01 8 8896.8.1.001 0.01 8 8896.8.1.001 0.002 8 8970.8.1.001 0.002 8 8970.8.1.002 8 8970.002 8 8970.002 8 8970.8.1.	0.909 0.416 0.903 0.903 0.905 0.905	, , , ,	Las transportscholl programment provinsion of provinsion of the second benerging bene	1,311 1,321 4,315 4,315 1,000 2,057 847 7,617 1,868 6,004 323 7,521 6,123 1,871 6,123 1,871 6,123 1,871 6,123 1,871 0,588		The Decision of Control Television of Control Televisio of Control Television of Control Television of Co	0.356 0.372 0.567 0.565 0.456 0.667	Origin or show Design White-Houseshow White-Houseshow White	4.395 + 4.777 + 3.080 + 4.2077 + 4.2077 + 4.207 + 4.080 + 4.207 + 4.080 + 4.080 + 4.090 + 4.209 + 5.344 + 4.209 + 5.344 + 4.209 + 6.600 + 4.209 + 4	0.000020.0100 01 0.000270.100 00 0.000271.100 00 0.000271.100 00 0.000271.110 00 0.000271.100 00 0.000271.1000000000000000000000000000000	5 6 0.732 0.009 0.145 0 0.145 0 0.145 0 0.145 0 0.145 0 0.145 0 0.145 0 0.155 0 0 0 0 0 0 0 0 0 0 0 0 0	Compare Janves / La Compar	(168) (177) (160) (160) (177) (177) (177) (177) (177) (177) (177) (177) (177) (177) (178) (179)	6.39(3,6,5)7, 48(3) (39(3,6,5)7, 48(3) (39(3,6,5)7, 48(3) (39(3,6,1)7, 68(4) (39(3,6,1)7, 68(4)) (39(3,6,1)7, 68(4)) (39(3,6,	0.337 0.788 0.699 0.182	Managan Managan Managan Anghangan Man Wenne Managan Managan Kata of Calabata Man Man Man Man Man Man Man Man Man Ma	4,717 (1990 2,997 8,67 7,917 1,860 6,004 338 7,931 4,999 1,364 1,221 0,20		6 (832) 963,138 0 (4 6 882) 963,139 0 (4 6 882) 963,139 0 (2 6 882) 263,100 (2 6 882) 263,100 (2 6 882) 460,87 0 (20 6 892) 470,87 0 (20 6 892) 470,8	(00) 4 2 385 303 305 305 402 402 3 5

Subgroup analyses and interaction test of the association between vitamin intake and sarcopenia. (A–J) Represented the association of vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9, vitamin B1, vitamin C, vitamin C, vitamin K, and sarcopenia, respectively.

As one person ages, the endogenous antioxidant defense system of the body is impaired and leads to an excessive accumulation of ROS that results in mitochondrial dysfunction and oxidative damage to muscle tissues. This process may directly or indirectly contribute to skeletal muscle atrophy (28, 29). Antioxidant vitamins, such as VC and VE, have been shown to prevent muscle protein oxidation and degradation, thereby helping to preserve muscle function and promote the antioxidant activity of

Variables	The range of dietary vitamin levels	Model 1	<i>P</i> -value	Model 2	<i>P</i> -value	Model 3	<i>P</i> -value		
Log (VA) (mcg)									
Q1	-0.69-5.72	1		1		1			
Q2	5.72-6.64	0.575 (0.409,0.808)	0.002	0.558 (0.400,0.778)	< 0.001	0.521 (0.383,0.708)	< 0.001		
Q3	6.64-8.90	0.691 (0.445,1.072)	0.097	0.658 (0.425,1.020)	0.061	0.551 (0.368,0.824)	0.005		
p for trend			0.052		0.030		0.002		
Log (VB1) (mg)									
Q1	-3.05-0.16	1		1		1			
Q2	0.16-0.90	1.288 (0.868,1.912)	0.204	1.260 (0.867,1.832)	0.220	1.212 (0.815,1.804)	0.333		
Q3	0.90-6.46	0.963 (0.609,1.524)	0.871	0.964 (0.612,1.519)	0.873	0.846 (0.506,1.412)	0.513		
p for trend			0.997		0.985		0.583		
Log (VB2) (mg)									
Q1	-2.78-0.36	1		1		1			
Q2	0.36-1.12	0.824 (0.552,1.230)	0.338	0.797 (0.536,1.187)	0.258	0.725 (0.484,1.086)	0.116		
Q3	1.12-5.36	0.752 (0.500,1.131)	0.168	0.708 (0.472,1.062)	0.093	0.612 (0.401,0.932)	0.023		
p for trend			0.140		0.072		0.018		
Log (VB3) (mg)									
Q1	0.32-2.96	1		1		1			
Q2	2.96-3.64	1.032 (0.680,1.568)	0.880	0.992 (0.651,1.513)	0.971	0.912 (0.586,1.418)	0.676		
Q3	3.64-7.83	0.898 (0.586,1.377)	0.616	0.868 (0.565,1.334)	0.512	0.512 0.783 (0.481,1.275)			
p for trend			0.651		0.523		0.316		
Log (VB6) (mg)									
Q1	-2.59-0.39	1		1		1			
Q2	0.39-1.26	0.941 (0.627,1.411)	0.764	0.915 (0.598,1.401)	0.678	0.854 (0.543,1.344)	0.487		
Q3	1.26-9.21	0.636 (0.428,0.946)	0.026	0.629 (0.412,0.959)	0.032	0.570 (0.369,0.880)	0.013		
p for trend			0.033		0.036		0.013		
Log (VB9) (mcg)									
Q1	2.60-5.89	1		1		1			
Q2	5.89-6.78	0.972 (0.615,1.539)	0.903	0.966 (0.618,1.508)	0.876	0.889 (0.570,1.387)	0.596		
Q3	6.78-9.76	0.941 (0.597,1.485)	0.791	0.930 (0.594,1.456)	0.745	0.837 (0.529,1.324)	0.438		
p for trend			0.792		0.742		0.428		
Log (VB12) (mcg)									
Q1	-5.30-1.11	1		1		1			
Q2	1.11-2.42	0.871 (0.577,1.314)	0.504	0.853 (0.563,1.293)	0.447	0.793 (0.524,1.201)	0.266		
Q3	2.42-11.00	0.719 (0.477,1.083)	0.112	0.729 (0.485,1.096)	0.126	0.676 (0.457,1.000)	0.050		
p for trend			0.112		0.122		0.046		
Log (VC) (mg)									
Q1	-2.30-3.55	1		1		1			
Q2	3.55-5.00	1.057 (0.723,1.545)	0.771	1.081 (0.731,1.600)	0.690	1.061 (0.713,1.578)	0.765		

 TABLE 3
 Multi-variate adjusted odds ratios (95% CIs) of risks of Sarcopenia in relation to different dietary vitamins levels among participants in NHANES

 2011–2018 after propensity score matching (PSM).

(Continued)

Variables	The range of dietary vitamin levels	Model 1	<i>P</i> -value	Model 2	<i>P</i> -value	Model 3	<i>P</i> -value		
Q3	5.00-9.64	0.661 (0.450,0.970)	0.035	0.675 (0.457,0.997)	0.048	0.639 (0.431,0.948)	0.027		
p for trend			0.044		0.059		0.034		
Log (VD) (mcg)									
Q1	-3.00-0.77	1		1		1			
Q2	0.77-2.56	0.807 (0.511,1.274)	0.351	0.812 (0.519,1.268)	0.352	0.772 (0.493,1.208)	0.249		
Q3	2.56-7.19	0.919 (0.567,1.490)	0.728	0.969 (0.614,1.529)	0.890	0.882 (0.565,1.376)	0.572		
p for trend			0.681		0.806		0.498		
Log (VE) (mg)									
Q1	-2.81-1.67	1		1		1			
Q2	1.67-2.42	1.347 (0.928,1.954)	0.115	1.326 (0.917,1.916)	0.130	1.218 (0.827,1.794)	0.309		
Q3	2.42-5.04	0.926 (0.566,1.515)	0.755	0.888 (0.543,1.452)	0.630	0.778 (0.473,1.280)	0.315		
p for trend			0.967		0.832		0.449		
Log (VK) (mcg)									
Q1	-0.36-3.93	1		1		1			
Q2	3.93-4.99	0.901 (0.591,1.373)	0.621	0.887 (0.585,1.345)	0.566	0.841 (0.557,1.268)	0.399		
Q3	4.99–10.72	0.791 (0.507,1.233)	0.295	0.783 (0.499,1.228)	0.280	0.733 (0.468,1.148)	0.170		
p for trend			0.297		0.276		0.160		

TABLE 3 (Continued)

Data are presented as OR (95% CI) unless otherwise indicated. Model 1, without adjustment. Model 2, adjusted for gender, age, ethnicity, educational level, marriage, PIR and BMI. Model 3, adjusted for model 2 variables as well as the disease history (diabetes, hypertension, and malignancy), total caloric intake, smoking status, alcohol drinking status, and physical activity.

glutathione (30, 31). Some observational studies indicate a strong association between VC intake and plasma VC levels with physical function and muscle mass in the old (32, 33), suggesting that adequate VC intake may help in the prevention of sarcopenia, a finding consistent with our results. Similarly, cross-sectional studies proved that higher VE intake is beneficial for muscle and skeletal health (30), with higher VE and fat intake linked to a lower incidence of sarcopenia (34). Further prospective research is necessary for examining the causal relationship between VC, VE, and the onset of sarcopenia. Few have delved into the connection of VA with sarcopenia. More research has focused on carotenoids, the main source of VA for the body, including acarotene, β-carotene, γ-carotene, lycopene, lutein, zeaxanthin, and cryptoxanthin. Carotenoids, VC, and VE are collectively considered the most important antioxidants in the diet (32). A prospective study has shown that higher carotenoid intake in middle-aged and old individuals [age (61 \pm 9 years)] is associated with increased grip strength and walking speed (35). In this study, VA was quantified in terms of retinol activity equivalents, providing a novel approach for future research. Reports on the function of VK in skeletal muscle are limited. To date, only a few studies demonstrated that VK helps to protect skeletal muscle. Research indicates the role of VK in modulating energy metabolism in skeletal muscle. VK-2 (MK4) has been shown to improve electron transfer in mitochondria and increase ATP production (36). It also helps maintain mitochondrial balance in skeletal muscle, a critical factor in preventing sarcopenia (37). Recently, a study based on NHANES explored the combined intake of vitamins A, C, E, and K as an antioxidant vitamin nutritional pattern and its effects on sarcopenia. The results demonstrated that the combined intake of these vitamins was significantly correlated with a reduced prevalence of sarcopenia, suggesting that this nutritional pattern could offer a new strategy for preventing muscle mass loss. Further prospective research is needed (13).

B vitamins, particularly VB1, VB3, VB6, VB9, and VB12, not only serve as cofactors in muscle synthesis but are also regarded as neurotrophic agents involved in bioenergetic and nutritional pathways. Current research predominantly focuses on the association between VB6, VB9, VB12, and sarcopenia. Elevated levels of homocysteine have been linked to a decline in muscle strength and gait speed, whereas vitamins B6, B9, and B12 have been shown to reduce serum homocysteine levels, thereby potentially offering benefits in sarcopenia prevention and control. A Dutch study evaluated the dietary habits and use of nutritional supplements among 227 old individuals (≥65 years) in the community via a food frequency questionnaire. The intake of VB6 and VB9 was markedly lower by 10%-18% in old individuals with sarcopenia compared with controls (P < 0.05) (20). Another case-control study included 66 old individuals with sarcopenia [mean age (71 \pm 4 years)] and 66 age- and gender-matched controls and showed that the sarcopenia group had a 22% lower VB12 intake and 15% lower serum VB12 concentrations than the control cohort (P < 0.05 and P = 0.015) (11). Recently, one study based on the NHANES database investigated the link of VB1 and B2 intake to early-onset sarcopenia in American adults, revealing that higher intakes of VB1 and B2 may reduce the

risk of developing early-onset sarcopenia (14), which aligns with our findings.

Our subgroup analysis also yielded some novel findings. The results of the age subgroup analysis indicate that, with increasing age, the number of vitamin types negatively correlated with sarcopenia increases. In the population under 30, only the intake of VE (P = 0.042) and VK (P = 0.006) showed a negative correlation with sarcopenia prevalence. However, in individuals aged 50 and above, the intake of VA (P = 0.011), VB3 (P =0.016), VB9 (P = 0.028), VB12 (P = 0.014), VE (P = 0.008), and VK (P = 0.019) were all negatively correlated with sarcopenia. Age-related physiological changes, such as declines in digestive and absorption functions, increased risk of chronic diseases, and multiple vitamin deficiencies, may be significant contributing factors to this phenomenon. Future longitudinal studies are necessary to clarify the causal relationship between vitamin intake and sarcopenia and to optimize dietary recommendations for the old population. The diabetes subgroup analysis indicated that higher intakes of VA (P = 0.028), VB3 (P = 0.025), and VE (P= 0.022) notably reduced the risk of sarcopenia (P < 0.05). This finding differs from that of a previous prospective study and may be due to variations in the participant age and methods used to assess muscle mass. This study included 197 diabetic patients aged \geq 65 years, with 93 individuals exhibiting a decline in muscle mass during an average 13.7-month follow-up. The intake of VB1 (P = 0.031), VB12 (P = 0.049), and VD (P = 0.004) was markedly lower than in those without muscle mass decline (38). In our baseline data, a statistically significant difference was not found in the proportion of men and women with sarcopenia, which contradicts previous studies (39, 40). This discrepancy may arise because prior studies included participants aged over 60 years, whereas our study included individuals aged under 60, a period during which estrogen continues to influence the metabolism and function of skeletal muscles in females (41). Notably, our genderspecific subgroup analysis revealed distinct protective effects: VB6, VB9, and VB12 exhibited stronger protective effects in men, while VC and VK had more pronounced protective effects in women. The specific mechanisms underlying these gender differences warrant further investigation, but these findings provide new references for developing gender-specific strategies for sarcopenia prevention. Sensitivity analysis demonstrates that the results showing an inverse correlation between the intake of vitamins VA, VB2, VB6, and VC and sarcopenia are more robust, likely due to propensity score matching, which better controlled for confounding bias between the two groups. Additionally, the inclusion of total caloric intake as a confounding factor further verified these findings. Future prospective studies with larger sample sizes are necessitated to elucidate the relationship between the intake of other vitamins and sarcopenia.

In our study, patients were at the age of 20–59, while sarcopenia is typically considered an age-related condition. Recent studies have revealed that some individuals begin to experience muscle wasting in midlife or even in their youth (42–44). This earlyonset muscle loss is referred to as early-onset sarcopenia (45– 47). Clinically, early-onset sarcopenia is associated with a poorer prognosis compared to typical sarcopenia (48). Patients with early-onset sarcopenia represent a unique high-risk group, and preventive and intervention strategies can effectively delay disease progression, thereby alleviating the burden on both patients and the healthcare system (48). In addition to nutritional interventions, exercise is a key measure in preventing sarcopenia. Resistance training, based on strength exercises, has been a proven safe and effective method. Individualized and periodic resistance training programs can enhance muscle strength, help maintain muscle mass, and counteract the progression of sarcopenia (49). The primary variables to consider when designing a resistance training program include training frequency, exercise selection, intensity, volume, and rest periods. It is recommended to perform training twice a week, combining upper and lower body exercises with a relatively high intensity for 1–3 sets of 6–12 repetitions per set (50).

Our study is the largest investigation to date into the relationship between the levels of 11 vitamins and the risk of sarcopenia, accounting for numerous potential confounding factors. Moreover, the majority of prior studies have focused on old populations, who are particularly vulnerable to malnutrition, oxidative stress, and declines in neurological integrity. In contrast, our study encompasses a nationally representative sample of Americans whose ages vary from 20 to 59, providing valuable insights for customizing vitamin intake based on life stages and conditions. However, our study does have certain limitations. First, it is cross-sectional and conducted at a single center, thus precluding the establishment of a causal relationship between vitamin levels and sarcopenia, so prospective cohort studies should be performed to confirm these results. Additionally, the sensitivity analysis shows that the results are not robust for all vitamins. Future studies with larger sample sizes or prospective designs are needed to further clarify this.

5 Conclusion

In conclusion, within a nationally representative group of American adults, the associations of the levels of 11 vitamins with the risk of sarcopenia were elucidated. In the future, researchers should elucidate whether interventions targeting the combination of vitamins, with or without other nutrients, can increase muscle mass in middle-aged and older populations, decrease the prevalence of sarcopenia, and ameliorate the life of sarcopenia sufferers.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

YQ: Conceptualization, Methodology, Writing – original draft, Writing – review & editing. FZ: Formal analysis, Investigation, Writing – review & editing. XZ: Formal analysis, Investigation, Writing – review & editing. XW: Funding acquisition, Resources, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the 2022 Nantong Municipal Health Commission Scientific Research Project (Mandatory) [Grant No.: MS2022026].

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative Al statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. (2019) 393:2636-46. doi: 10.1016/S0140-6736(19)31138-9

2. Ethgen O, Beaudart C, Buckinx F, Bruyère O, Reginster JY. The future prevalence of sarcopenia in Europe: a claim for public health action. *Calcif Tissue Int.* (2017) 100:229–34. doi: 10.1007/s00223-016-0220-9

3. Cao L, Morley JE. Sarcopenia is recognized as an independent condition by an international classification of disease, tenth revision, clinical modification (ICD-10-CM) code. *J Am Med Dir Assoc.* (2016) 17:675–7. doi: 10.1016/j.jamda.2016. 06.001

4. Gao K, Cao LF, Ma WZ, Gao YJ, Luo MS, Zhu J, et al. Association between sarcopenia and cardiovascular disease among middle-aged and older adults: findings from the China health and retirement longitudinal study. *EClinicalMedicine*. (2022) 44:101264. doi: 10.1016/j.eclinm.2021.101264

 Yeung SSY, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CGM, et al. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. (2019) 10:485–500. doi: 10.1002/jcsm.12411

6. Bruyère O, Beaudart C, Ethgen O, Reginster JY, Locquet M. The health economics burden of sarcopenia: a systematic review. *Maturitas.* (2019) 119:61–9. doi: 10.1016/j.maturitas.2018.11.003

7. Zanker J, Scott D, Reijnierse EM, Brennan-Olsen SL, Daly RM, Girgis CM, et al. Establishing an operational definition of sarcopenia in Australia and New Zealand: Delphi method based consensus statement. *J Nutr Health Aging*. (2019) 23:105–10. doi: 10.1007/s12603-018-1113-6

8. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing.* (2010) 39:412–23. doi: 10.1093/ageing/afq034

9. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci.* (2014) 69:547–58. doi: 10.1093/gerona/glu010

10. Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Sarcopenia: an overview. *Aging Clin Exp Res.* (2017) 29:11–7. doi: 10.1007/s40520-016-0704-5

11. Verlaan S, Aspray TJ, Bauer JM, Cederholm T, Hemsworth J, Hill TR, et al. Nutritional status, body composition, and quality of life in community-dwelling sarcopenic and non-sarcopenic older adults: a case-control study. *Clin Nutr.* (2017) 36:267–74. doi: 10.1016/j.clnu.2015.11.013

12. Ganapathy A, Nieves JW. Nutrition and sarcopenia-what do we know? *Nutrients*. (2020) 12:1755. doi: 10.3390/nu12061755

13. Liu Y, Liu X, Duan L, Zhao Y, He Y, Li W, et al. Associations of micronutrient dietary patterns with sarcopenia among US adults: a population-based study. *Front Nutr.* (2024) 11:1301831. doi: 10.3389/fnut.2024.1301831

14. Yang S, Dong Z, Zhao J, Yuan L, Xiao Y, Luo X, et al. Association of vitamins B1 and B2 intake with early-onset sarcopenia in the general adult population of the US: a cross-sectional study of NHANES data from 2011 to 2018. *Front Nutr.* (2024) 11:1369331. doi: 10.3389/fnut.2024.1369331

15. Tessier AJ, Wing SS, Rahme E, Morais JA, Chevalier S. Physical functionderived cut-points for the diagnosis of sarcopenia and dynapenia from the Canadian longitudinal study on aging. J Cachexia Sarcopenia Muscle. (2019) 10:985-99. doi: 10.1002/jcsm.12462

16. McPhee JS, French DP, Jackson D, Nazroo J, Pendleton N, Degens H. Physical activity in older age: perspectives for healthy ageing and frailty. *Biogerontology*. (2016) 17:567–80. doi: 10.1007/s10522-016-9641-0

17. Yang A, Lv Q, Chen F, Wang Y, Liu Y, Shi W, et al. The effect of vitamin D on sarcopenia depends on the level of physical activity in older adults. *J Cachexia Sarcopenia Muscle.* (2020) 11:678–89. doi: 10.1002/jcsm.12545

18. Shea MK, Fielding RA, Dawson-Hughes B. The effect of vitamin D supplementation on lower-extremity power and function in older adults: a randomized controlled trial. *Am J Clin Nutr.* (2019) 109:369–79. doi: 10.1093/ajcn/nqy290

19. Balboa-Castillo T, Struijk EA, Lopez-Garcia E, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillon P. Low vitamin intake is associated with risk of frailty in older adults. *Age Ageing.* (2018) 47:872–9. doi: 10.1093/ageing/afy105

20. Ter Borg S, de Groot LC, Mijnarends DM, de Vries JH, Verlaan S, Meijboom S, et al. Differences in nutrient intake and biochemical nutrient status between sarcopenic and nonsarcopenic older adults-results from the Maastricht sarcopenia study. *J Am Med Dir Assoc.* (2016) 17:393–401. doi: 10.1016/j.jamda.2015.12.015

21. Wilkinson TJ, Miksza J, Yates T, Lightfoot CJ, Baker LA, Watson EL, et al. Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study. *J Cachexia Sarcopenia Muscle.* (2021) 12:586–98. doi: 10.1002/jcsm.12705

22. Yang W, Gui Q, Chen L, Xu K, Xu Z. Associations between dietary protein and vitamin intake and the physical functioning of older adults with sarcopenia. *Eur Geriatr Med.* (2018) 9:311–20. doi: 10.1007/s41999-018-0049-z

23. Alliband KH, Parr T, Jethwa PH, Brameld JM. Active vitamin D increases myogenic differentiation in C2C12 cells via a vitamin D response element on the myogenin promoter. *Front Physiol.* (2023) 14:1322677. doi: 10.3389/fphys.2023.1322677

24. Stratos I, Schleese S, Rinas I, Vollmar B, Mittlmeier T. Effect of calcitriol and vitamin D receptor modulator 2 on recovery of injured skeletal muscle in wistar rats. *Biomedicines*. (2023) 11:2477. doi: 10.3390/biomedicines11092477

25. Fonte FK, Spinoza ED, Carvalho VA, Albuquerque R, Nebuloni CC, Santos FCD, et al. Relationship of protein, calcium and vitamin D consumption with body composition and fractures in oldest-old independent people. *Clin Nutr ESPEN*. (2024) 59:398–403. doi: 10.1016/j.clnesp.2023.12.008

26. Borda MG, Samuelsson J, Cederholm T, Baldera JP, Pérez-Zepeda MU, Barreto GE, et al. Nutrient intake and its association with appendicular total lean mass and muscle function and strength in older adults: a population-based study. *Nutrients*. (2024) 16:568. doi: 10.3390/nu16040568

27. Rosendahl-Riise H, Spielau U, Ranhoff AH, Gudbrandsen OA, Dierkes J. Vitamin D supplementation and its influence on muscle strength and mobility in community-dwelling older persons: a systematic review and meta-analysis. *J Hum Nutr Diet.* (2017) 30:3–15. doi: 10.1111/jhn.12394

28. Damiano S, Muscariello E, La Rosa G, Di Maro M, Mondola P, Santillo M. Dual role of reactive oxygen species in muscle function: can antioxidant dietary supplements counteract age-related sarcopenia? *Int J Mol Sci.* (2019) 20:3815. doi: 10.3390/ijms20153815

29. Kolesar JE, Safdar A, Abadi A, MacNeil LG, Crane JD, Tarnopolsky MA, et al. Defects in mitochondrial DNA replication and oxidative damage

in muscle of mtDNA mutator mice. Free Radic Biol Med. (2014) 75:241-51. doi: 10.1016/j.freeradbiomed.2014.07.038

30. Mulligan AA, Hayhoe RPG, Luben RN, Welch AA. Positive associations of dietary intake and plasma concentrations of vitamin E with skeletal muscle mass, heel bone ultrasound attenuation and fracture risk in the EPIC-norfolk cohort. *Antioxidants*. (2021) 10:159. doi: 10.3390/antiox10020159

31. Passerieux E, Hayot M, Jaussent A, Carnac G, Gouzi F, Pillard F, et al. Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial. *Free Radic Biol Med.* (2015) 81:158–69. doi: 10.1016/j.freeradbiomed.2014.09.014

32. Welch AA, Jennings A, Kelaiditi E, Skinner J, Steves CJ. Cross-sectional associations between dietary antioxidant vitamins C, E and carotenoid intakes and sarcopenic indices in women aged 18-79 years. *Calcif Tissue Int.* (2020) 106:331–42. doi: 10.1007/s00223-019-00641-x

33. Lewis LN, Hayhoe RPG, Mulligan AA, Luben RN, Khaw KT, Welch AA. Lower dietary and circulating vitamin C in middle- and older-aged men and women are associated with lower estimated skeletal muscle mass. *J Nutr.* (2020) 150:2789–98. doi: 10.1093/jn/nxaa221

34. Otsuka Y, Iidaka T, Horii C, Muraki S, Oka H, Nakamura K, et al. Dietary intake of vitamin E and fats associated with sarcopenia in community-dwelling older Japanese people: a cross-sectional study from the fifth survey of the ROAD study. *Nutrients*. (2021) 13:1730. doi: 10.3390/nu13051730

35. Sahni S, Dufour AB, Fielding RA, Newman AB, Kiel DP, Hannan MT, et al. Total carotenoid intake is associated with reduced loss of grip strength and gait speed over time in adults: the framingham offspring study. *Am J Clin Nutr.* (2021) 113:437–45. doi: 10.1093/ajcn/nqaa288

36. Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, et al. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. *Science.* (2012) 336:1306–10. doi: 10.1126/science.1218632

37. Boengler K, Kosiol M, Mayr M, Schulz R, Rohrbach S. Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue. *J Cachexia Sarcopenia Muscle.* (2017) 8:349–69. doi: 10.1002/jcsm.12178

38. Takahashi F, Hashimoto Y, Kaji A, Sakai R, Kawate Y, Okamura T, et al. Vitamin intake and loss of muscle mass in older people with type 2 diabetes: a prospective study of the KAMOGAWA-DM cohort. *Nutrients*. (2021) 13. doi: 10.3390/nu13 072335

39. Lee HJ, Choi JY, Hong D, Kim D, Min JY, Min KB. Sex differences in the association between sarcopenia and mild cognitive impairment in the older Korean population. *BMC Geriatr.* (2023) 23:332. doi: 10.1186/s12877-023-03911-4

40. Coin A, Perissinotto E, Enzi G, Zamboni M, Inelmen EM, Frigo AC, et al. Predictors of low bone mineral density in the elderly: the role of dietary intake, nutritional status and sarcopenia. *Eur J Clin Nutr.* (2008) 62:802–9. doi: 10.1038/sj.ejcn.1602779

41. Lu L, Tian L. Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen. *J Endocrinol.* (2023) 259:e230116. doi: 10.1530/JOE-23-0116

42. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing.* (2019) 48:601. doi: 10.1093/ageing/afz046

43. Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. *Clin Nutr.* (2007) 26:389–99. doi: 10.1016/j.clnu.2007.03.008

44. Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C. The developmental origins of sarcopenia. J Nutr Health Aging. (2008) 12:427–32. doi: 10.1007/BF02982703

45. Leser JM, Harriot A, Buck HV, Ward CW, Stains JP. Aging, osteo-sarcopenia, and musculoskeletal mechano-transduction. *Front Rehabil Sci.* (2021) 2:782848. doi: 10.3389/fresc.2021.782848

46. Moulin M, Ferreiro A. Muscle redox disturbances and oxidative stress as pathomechanisms and therapeutic targets in early-onset myopathies. *Semin Cell Dev Biol.* (2017) 64:213–23. doi: 10.1016/j.semcdb.2016.08.003

47. Blanquet M, Massoulié G, Boirie Y, Guiguet-Auclair C, Mulliez A, Anker S, et al. Handgrip strength to screen early-onset sarcopenia in heart failure. *Clin Nutr ESPEN*. (2022) 50:183–90. doi: 10.1016/j.clnesp.2022.05.019

48. Sousa AS, Guerra RS, Fonseca I, Pichel F, Ferreira S, Amaral TF. Financial impact of sarcopenia on hospitalization costs. *Eur J Clin Nutr.* (2016) 70:1046–51. doi: 10.1038/ejcn.2016.73

49. Cannataro R, Cione E, Bonilla DA, Cerullo G, Angelini F, D'Antona G. Strength training in elderly: An useful tool against sarcopenia. *Front Sports Act Living.* (2022) 4:950949. doi: 10.3389/fspor.2022.950949

50. Hurst C, Robinson SM, Witham MD, Dodds RM, Granic A, Buckland C, et al. Resistance exercise as a treatment for sarcopenia: prescription and delivery. *Age Ageing.* (2022) 51:afac003. doi: 10.1093/ageing/afac003